

# Longer and better lives for patients with atrial fibrillation: the 9th AFNET/EHRA consensus conference

Dominik Linz <sup>1,2</sup>, Jason G. Andrade <sup>3,4</sup>, Elena Arbelo <sup>5,6,7,8</sup>,  
Giuseppe Boriani <sup>9</sup>, Guenter Breithardt <sup>10,11</sup>, A. John Camm <sup>12</sup>,  
Valeria Caso <sup>13</sup>, Jens Cosedis Nielsen <sup>14</sup>, Mirko De Melis <sup>15</sup>,  
Tom De Potter <sup>16</sup>, Wolfgang Dichtl <sup>17</sup>, Søren Zoega Diederichsen <sup>18</sup>,  
Dobromir Dobrev <sup>19</sup>, Nicolas Doll<sup>20</sup>, David Duncker <sup>21</sup>, Elke Dworatzek<sup>22</sup>,  
Lars Eckardt <sup>11,23</sup>, Christoph Eisert <sup>24</sup>, Larissa Fabritz <sup>11,25,26,27</sup>,  
Michal Farkowski <sup>28</sup>, David Filgueiras-Rama <sup>7,29,30</sup>, Andreas Goette <sup>11,31</sup>,  
Eduard Guasch <sup>6,7,32</sup>, Guido Hack<sup>33</sup>, Stéphane Hatem <sup>34</sup>,  
Karl Georg Haeusler <sup>11,35</sup>, Jeff S. Healey <sup>36,37</sup>, Hein Heidbuechel <sup>38</sup>,  
Ziad Hijazi <sup>38,39,40</sup>, Lucas H. Hofmeister<sup>41</sup>, Leif Hove-Madsen <sup>7,42,43</sup>,  
Thomas Huebner<sup>24</sup>, Stefan Kääh <sup>8,44,45</sup>, Dipak Kotecha <sup>27,46</sup>,  
Katarzyna Malaczynska-Rajpold <sup>47,48</sup>, José Luis Merino <sup>49</sup>,  
Andreas Metzner <sup>50</sup>, Lluís Mont <sup>5,6,7</sup>, Ghulam Andre Ng <sup>51,52</sup>,  
Michael Oeff<sup>11,53</sup>, Abdul Shokor Parwani <sup>54</sup>, Helmut Puererfellner <sup>55</sup>,  
Ursula Ravens<sup>11,56</sup>, Michiel Rienstra <sup>57</sup>, Prashanthan Sanders <sup>58</sup>,  
Daniel Scherr <sup>59</sup>, Renate Schnabel <sup>11,26,50</sup>, Ulrich Schotten <sup>11,60</sup>,  
Christian Sohns <sup>61</sup>, Gerhard Steinbeck<sup>11,62</sup>, Daniel Steven <sup>11,63</sup>,  
Tobias Toennis <sup>26,50</sup>, Stylianos Tzeis <sup>64</sup>, Isabelle C. van Gelder <sup>57</sup>,  
Roderick H. van Leerdam<sup>65</sup>, Kevin Vernooij <sup>1</sup>, Manish Wadhwa<sup>66</sup>,  
Reza Wakili<sup>11,67,68</sup>, Stephan Willems <sup>11,26,69</sup>, Henning Witt <sup>22</sup>,  
Stef Zeemering <sup>60</sup>, and Paulus Kirchhof <sup>11,26,27,50\*</sup>

<sup>1</sup>Department of Cardiology, Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands; <sup>2</sup>Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; <sup>3</sup>Division of Cardiology, Vancouver General Hospital, Vancouver, Canada; <sup>4</sup>Montreal Heart Institute, Montreal, Canada; <sup>5</sup>Institut Clinic Cardiovascular, Hospital Clinic, Universitat de Barcelona, Barcelona, Catalonia, Spain; <sup>6</sup>Institut d'Investigació August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain; <sup>7</sup>Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain; <sup>8</sup>European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart—ERN GUARD-Heart; <sup>9</sup>Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Polyclinic of Modena, Modena, Italy; <sup>10</sup>Department of Cardiovascular Medicine, University Hospital, Münster, Germany; <sup>11</sup>Atrial Fibrillation NETWORK (AFNET), Muenster, Germany; <sup>12</sup>Cardiology Clinical Academic Group, Molecular and Clinical Sciences Institute, St. George's University of London, London, UK; <sup>13</sup>Stroke Unit, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy; <sup>14</sup>Department of Cardiology, Aarhus University Hospital and Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; <sup>15</sup>Bakken Research Center, Maastricht, The Netherlands; <sup>16</sup>Cardiovascular Center, OLV Hospital, Aalst, Belgium; <sup>17</sup>Department of Internal Medicine III, Cardiology and Angiology, Medical University Innsbruck, Innsbruck, Austria; <sup>18</sup>Department of Cardiology, Copenhagen University Hospital—Rigshospitalet, Copenhagen, Denmark; <sup>19</sup>Institute of Pharmacology, Faculty of Medicine, University Hospital Essen, University Duisburg-Essen, Essen, Germany; <sup>20</sup>Department of Cardiac Surgery, Schüchtermann-Klinik, Bad Rothenfelde, Germany; <sup>21</sup>Hannover Heart Rhythm Center, Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany; <sup>22</sup>Pfizer Pharma GmbH, Berlin, Germany; <sup>23</sup>Department of Cardiology II—Electrophysiology, University Hospital Münster, Münster, Germany; <sup>24</sup>Preventicus GmbH, Jena, Germany; <sup>25</sup>University Center of Cardiovascular Science, UHZ, UKE, Hamburg, Germany; <sup>26</sup>German Centre for Cardiovascular Research (DZHK), Partner Site: Hamburg/Kiel/Lübeck, Hamburg, Germany; <sup>27</sup>Institute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Birmingham, UK; <sup>28</sup>Department of Cardiology, Ministry of Interior and Administration, National Medical Institute, Warsaw, Poland; <sup>29</sup>Centro Nacional de Investigaciones Cardiovasculares (CNIC), Novel Arrhythmogenic Mechanisms Program, Madrid, Spain; <sup>30</sup>Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Cardiovascular Institute, C/ Profesor Martín Lagos, Madrid, Spain; <sup>31</sup>Department of Cardiology and Intensive Care Medicine, St Vincenz-Hospital Paderborn, Paderborn, Germany; <sup>32</sup>Clinic Barcelona, University of Barcelona, Barcelona, Spain; <sup>33</sup>Bristol-Myers Squibb GmbH & Co. KGaA, Munich, Germany; <sup>34</sup>IHU ICAN, Hospital Pitié-Salpêtrière, Paris, France; <sup>35</sup>Department of Neurology, Universitätsklinikum Würzburg (UKW), Würzburg, Germany; <sup>36</sup>Division of Cardiology, McMaster University, Hamilton, Ontario, Canada; <sup>37</sup>Population Health Research Institute, Hamilton, Ontario, Canada; <sup>38</sup>Antwerp University Hospital, Cardiovascular Sciences, University of Antwerp, Antwerp, Belgium; <sup>39</sup>Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden; <sup>40</sup>Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden; <sup>41</sup>Global Medical Affairs Bayer AG, Berlin, Germany; <sup>42</sup>Biomedical Research Institute Barcelona (IBB-CSIC), Barcelona, Spain; <sup>43</sup>IR Sant Pau, Hospital de Sant Pau, Barcelona, Spain; <sup>44</sup>Department of Medicine I, University Hospital, LMU Munich, Munich, Germany; <sup>45</sup>German Centre for Cardiovascular Research (DZHK), Partner Site Munich, Munich Heart Alliance, Munich, Germany; <sup>46</sup>NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Trust, Birmingham, UK; <sup>47</sup>Lister Hospital, East and North Hertfordshire NHS Trust, Stevenage, UK; <sup>48</sup>Royal Brompton Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK;

<sup>49</sup>La Paz University Hospital, IdiPaz, Autonomous University of Madrid, Madrid, Spain; <sup>50</sup>Department of Cardiology, University Heart & Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg, Germany; <sup>51</sup>Department of Cardiovascular Sciences, University of Leicester, Leicester, UK; <sup>52</sup>NIHR Leicester Biomedical Research Centre, Leicester, UK; <sup>53</sup>Cardiology Department, Medizinische Hochschule Brandenburg, Brandenburg/Havel, Germany; <sup>54</sup>Department of Cardiology, Deutsches Herzzentrum der Charité (CVK), Berlin, Germany; <sup>55</sup>Cardiological Department, Ordensklinikum Linz Elisabethinen, Linz, Austria; <sup>56</sup>Institute of Experimental Cardiovascular Medicine, University Clinic Freiburg, Freiburg, Germany; <sup>57</sup>University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; <sup>58</sup>Centre for Heart Rhythm Disorders, University of Adelaide and Royal Adelaide Hospital, Adelaide, Australia; <sup>59</sup>Division of Cardiology, Medical University of Graz, Graz, Austria; <sup>60</sup>Departments of Physiology, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands; <sup>61</sup>Herz- und Diabeteszentrum Nordrhein-Westfalen, Universitätsklinik der Ruhr-Universität Bochum, Klinik für Elektrophysiologie—Rhythmologie, Bad Oeynhausen, Germany; <sup>62</sup>Center for Cardiology at Clinic Starnberg, Starnberg, Germany; <sup>63</sup>Heart Center, Department of Electrophysiology, University Hospital Cologne, Cologne, Germany; <sup>64</sup>Cardiology Department, Mitera Hospital, Athens, Greece; <sup>65</sup>Royal Philips, Amsterdam, The Netherlands; <sup>66</sup>Medical Office, Philips Ambulatory Monitoring and Diagnostics, San Diego, CA, USA; <sup>67</sup>Department of Medicine and Cardiology, Goethe University, Frankfurt, Germany; <sup>68</sup>German Centre for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Germany; and <sup>69</sup>Asklepios Hospital St. Georg, Department of Cardiology and Internal Care Medicine, Faculty of Medicine, Semmelweis University Campus, Hamburg, Germany

Received 22 December 2023; accepted after revision 16 February 2024; online publish-ahead-of-print 9 April 2024

## Aims

Recent trial data demonstrate beneficial effects of active rhythm management in patients with atrial fibrillation (AF) and support the concept that a low arrhythmia burden is associated with a low risk of AF-related complications. The aim of this document is to summarize the key outcomes of the 9th AFNET/EHRA Consensus Conference of the Atrial Fibrillation Network (AFNET) and the European Heart Rhythm Association (EHRA).


## Methods and results

Eighty-three international experts met in Münster for 2 days in September 2023. Key findings are as follows: (i) Active rhythm management should be part of the default initial treatment for all suitable patients with AF. (ii) Patients with device-detected AF have a low burden of AF and a low risk of stroke. Anticoagulation prevents some strokes and also increases major but non-lethal bleeding. (iii) More research is needed to improve stroke risk prediction in patients with AF, especially in those with a low AF burden. Biomolecules, genetics, and imaging can support this. (iv) The presence of AF should trigger systematic workup and comprehensive treatment of concomitant cardiovascular conditions. (v) Machine learning algorithms have been used to improve detection or likely development of AF. Cooperation between clinicians and data scientists is needed to leverage the potential of data science applications for patients with AF.

## Conclusions

Patients with AF and a low arrhythmia burden have a lower risk of stroke and other cardiovascular events than those with a high arrhythmia burden. Combining active rhythm control, anticoagulation, rate control, and therapy of concomitant cardiovascular conditions can improve the lives of patients with AF.

## Graphical Abstract



\* Corresponding author. Tel: +49 (0)40 7410 52438; fax: +49 (0)40 7410 55862. E-mail address: p.kirchhof@uke.de

© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

**Keywords**

Atrial fibrillation • Artificial intelligence • Biomarkers • Heart failure • Atrial cardiomyopathy • Cognitive function • Dementia • Outcomes • Quality of care • Cost • Research • Rhythm management • Catheter ablation • Anticoagulation • Bleeding • Research priorities • Technology • Stroke • Integrated care • Screening • AFNET • EHRA • Guidelines • Consensus statement

**What's new?**

Recent evidence suggests important improvements to the management of patients with one atrial fibrillation (AF).

- (1) Active rhythm management should be part of the default initial treatment for patients with AF.
- (2) Patients with device-detected AF have a low burden of AF and a low risk of stroke. Anticoagulation prevents some strokes and also increases major but non-lethal bleeding.
- (3) More research is needed to improve stroke risk prediction in patients with AF, especially in those with a low AF burden. Biomolecules, genetics, and imaging can support this.

In summary, combining active rhythm control, anticoagulation, rate control, and therapy of concomitant cardiovascular conditions can improve the lives of patients with AF.

**Introduction**

The year 2023 is the first year since 2011 in which three hot line presentations of clinical trials in patients with atrial fibrillation (AF) were presented at the annual congress of the European Society of Cardiology (ESC) and simultaneously published in the *New England Journal of Medicine* (CASTLE-HTx, ADVENT, and NOAH-AFNET 6).<sup>1–3</sup> In November 2023, ARTESiA was presented and published.<sup>4</sup> Unlike in 2011, when the focus was on anticoagulation,<sup>5–7</sup> two of the trials presented at ESC evaluated AF ablation,<sup>2,3</sup> the most effective method for active rhythm management. The two other large trials, although primarily assessing the efficacy and safety of anticoagulation in patients with device-detected AF, found a low stroke risk in a population with risk factors and a very low AF burden, highlighting the possible role of arrhythmia burden for stroke risk.<sup>1,4</sup> This shift from evaluating the effect of anticoagulation towards evaluating active rhythm control management in clinical trials highlights the recent growth in this clinical area (Figure 1). From 11–13 September 2023, experts from academia and industry met for the 9th AFNET/EHRA consensus conference of the Atrial Fibrillation NETWORK (AFNET) and the European Heart Rhythm Association (EHRA) to discuss these recent findings. To acknowledge the 20th anniversary of AFNET, the 9th AFNET/EHRA consensus conference was held in Münster, Germany, the home of AFNET.

**Methods**

The 9th AFNET/EHRA consensus conference brought together 83 international interdisciplinary experts including arrhythmia and heart failure specialists, pharmacologists, basic and translational scientists, general practitioners, neurologists, nurse practitioners, epidemiologists, clinical trialists, and health economists in Münster, Germany on 11–13 September 2023. The conference started with four sessions of expert talks summarizing recent developments in the field. Thereafter, the participants split into six breakout groups to discuss specific topics. Each break-out group summarized their thoughts and statements on posters and presented them to the plenary. These were discussed and adapted in poster walk-through sessions. The consensus summarized here integrates this iterative, intensive dialogue in each


group and in the plenum, using formal and informal feedback. Refinement of the consensus and integration of new data<sup>4,8,9</sup> was done during the writing process. Details of the methodology have been described before.<sup>10–13</sup>

**Active rhythm management: from symptom control to outcome reduction**

Atrial fibrillation guidelines recommend active rhythm control to improve symptoms in patients with AF. Since the release of the 2020 ESC AF guidelines, new data indicate that patients with recent onset AF and stroke risk factors<sup>14</sup> and those with heart failure with reduced ejection fraction have better cardiovascular outcomes on rhythm control therapy.<sup>3,15,16</sup> This evidence supports the use of early rhythm control irrespective of symptoms. The trials do not show safety signals associated with rhythm control. The safety of modern rhythm control is confirmed in analyses of large electronic health records.<sup>17–19</sup> Furthermore, the risk of stroke is low in patients with risk factors and a very low burden of device-detected AF (see 'Atrial fibrillation burden in patients with electrocardiogram-diagnosed atrial fibrillation and in patients with device-detected atrial fibrillation' section). This suggests that a reduction in arrhythmia burden could explain the outcome-reducing effect of rhythm control therapy. The concept of AF burden reduction as a component of treating patients with AF has been highlighted in the recent 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of AF.<sup>20</sup> Taking this in context with earlier trials such as ATHENA,<sup>21,22</sup> the group sees a paradigm shift that moves rhythm control from a symptom-improving 'lifestyle therapy' to an outcome-reducing treatment to reduce stroke, heart failure, and, to a lesser extent, acute coronary syndrome and cardiovascular death.

**Identification of patients suitable for rhythm control**

Currently, only a small minority of patients with AF are treated with rhythm control therapy. Based on the outcome-reducing effects of early rhythm control and AF ablation, patients with AF should, by default, undergo at least one attempt of active rhythm control (Figure 2). This may include a 'diagnostic cardioversion' to unmask AF-related symptoms and arrhythmia-induced cardiomyopathy. Left ventricular dysfunction should probably encourage rhythm control.<sup>3,15,16,23</sup> Early rhythm control reduced outcomes in patients with heart failure.<sup>23</sup> Atrial fibrillation ablation reduced cardiovascular events compared with medical therapy in two randomized trials, CASTLE-AF and CASTLE-HTx,<sup>3,15</sup> and in a pre-specified sub-analysis of the CABANA trial.<sup>24</sup> A few patients, who experience a good symptom control by rate control alone and in whom preventing cardiovascular events is no longer relevant (for example due to limited life expectancy or advanced age), may opt to not receive rhythm control therapy.



**Figure 1** Timeline of landmark trials in atrial fibrillation management on active rhythm management (left) and stroke prevention (right) from 2000 until today. The studies are colour-coded based on their size (from light to dark: <1000, 1000–10 000, and >10 000 participants), and ongoing studies are shown in orange. AAD, antiarrhythmic drugs; AF, atrial fibrillation; CA, catheter ablation; CV, cardiovascular; ECV, electrical cardioversion; ED, emergency department; HFrEF, heart failure with reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; Htx, heart transplantation; LAAO, left atrial appendage occlusion; OMT, optimal medical treatment; NOACs, novel oral anticoagulant drugs; PVI, pulmonary vein isolation; VKA, vitamin K antagonist.

## Role of atrial fibrillation ablation for delivering early rhythm control


The outcome-reducing effect of early rhythm control was achieved using antiarrhythmic drugs in most patients.<sup>25</sup> Attaining sinus rhythm was the main mediator of outcome reduction in EAST-AFNET 4.<sup>26</sup> The EAST-AFNET 4 trial also showed that early and systematic rhythm control is effective across AF patterns, including paroxysmal AF, persistent AF, and first-diagnosed AF.<sup>27</sup> Antiarrhythmic drugs remain a key component of rhythm control therapy. Atrial fibrillation ablation reduced symptoms,<sup>28</sup> psychological distress,<sup>29</sup> and arrhythmia burden<sup>30</sup> more than antiarrhythmic drug therapy. Ongoing and planned trials are evaluating whether AF ablation can also reduce cardiovascular events [CABA-HFPEF DZHK27 trial (NCT05508256), EAST<sup>high</sup>-AFNET 11, and others].

## Improving atrial fibrillation ablation

Pulmonary vein isolation (PVI) remains the main target for AF ablation. The STAR-AF II,<sup>31</sup> CAPLA,<sup>32</sup> and DECAAF II<sup>33</sup> studies showed

that empiric placement of additional ablation lines or magnetic resonance-guided ablation of fibrotic areas does not improve AF rhythm outcome after AF ablation compared with PVI alone. Several smaller recent trials comparing additional AF ablation targets to PVI only, including ERASE-AF,<sup>34</sup> showed a mix of neutral outcomes and improved prevention of recurrent AF. Additional studies, such as COAST AF (NCT03347227) and STAR-AF III (NCT04428944), will further evaluate additional ablation strategies on top of PVI. Recent randomized trials evaluating hybrid AF ablation combining surgical and endocardial ablation approaches, including CEASE-AF<sup>35</sup> (71.6% vs. 39.2%) and HARTCAP<sup>36</sup> (89% vs. 41%), showed good sinus rhythm maintenance without increased procedural complications in patients with persistent AF who have more recurrences of AF after PVI.<sup>37,38</sup>

Pulsed field ablation (PFA), a non-thermal energy source, conceptually targets cardiomyocytes and may spare other cell types. This conceptual advantage does not translate into better rhythm control in the ADVENT trial.<sup>2</sup> So far, there are very few reports of oesophageal complications or phrenic nerve injuries persisting past hospital discharge, comparable with cryo-balloon-based PVI,<sup>39</sup> and major



complications (pericardial tamponade, stroke, and stroke resulting in death) appear low at 1.6%.<sup>40</sup> More data are collected to define the efficacy and safety of PFA as an energy source for AF ablation.

## New antiarrhythmic drugs

Despite the advances in ablation therapy, there remains an unmet need for effective and safe antiarrhythmic drugs. Such compounds will need to demonstrate improvements compared with existing drugs that show good efficacy and safety when used in appropriate patients.<sup>14</sup> The development of antiarrhythmic agents has declined over the last decades,<sup>41</sup> but several promising compounds targeting ion channels are currently in clinical development (Table 1). Small conductance  $Ca^{2+}$ -activated  $K^{+}$  (SK) channels are up-regulated in patients with AF.<sup>42</sup> In a Phase 2 proof-of-concept study, a relatively selective SK-channel blocker successfully met efficacy and safety endpoints for pharmacological cardioversion of patients with recent-onset AF.<sup>43</sup> A Phase 1 study for a second-generation oral lead compound (AP31969) for sinus rhythm maintenance is leading to the planning of a Phase 2 study in patients with implantable loop recorders. HSY244 is a novel antiarrhythmic drug with the undisclosed mechanism of action and has been evaluated concerning efficacy for cardioversion of AF. The programme was terminated in 2023 based on business decisions (NCT04582409). HBI-3000 is a multi-channel blocker, which was well tolerated in the Phase 1 clinical trial and is currently investigated in a Phase 2 trial for acute intravenous cardioversion of patients with recent-onset AF (NCT04680026). An oral multi-channel amiodarone analogue with a relatively short elimination half-life, known as budiodarone, was successfully investigated in PASCAL, a Phase 2 study in patients with recurrent AF documented with pacemakers, and awaits further development. Additional, ongoing work aims to develop inhalable formulations of antiarrhythmic drugs and the repurposing of drugs approved for other indications (e.g. oral doxapram, colchicine, and metformin and injection of botulinum toxin type A into epicardial fat pads) as antiarrhythmic drug therapy in patients with AF (Table 1). Ranolazine is approved as an antianginal agent in Europe, and in the USA, it is also approved for the management of long QT3 syndrome.

It is a late sodium current inhibitor with a minor inhibitory effect on the HERG current. It is being used, often in combination with amiodarone, for the suppression of AF recurrences.

## Rate control drugs and ablate and pace

Rate control therapy remains an important component of rate and rhythm management in patients with AF.<sup>10</sup> The concept of rate control, enabling better cardiac function by slowing and regularizing ventricular rate during episodes of AF, remains unchanged. Almost all rhythm control trials are conducted against a background therapy of rate control,<sup>14</sup> typically using beta-blockers, calcium channel antagonists, and digitalis glycosides.<sup>44,45</sup> Medical rate control therapy should be part of active rhythm management in patients with AF, considering the rate-controlling effects of several antiarrhythmic drugs, including amiodarone, dronedarone, propafenone, and sotalol. The recent APAF-CRT trial showed that there is a role for rate control using a pace-and-ablate strategy in symptomatic heart failure patients with permanent AF to improve clinical outcome.<sup>46</sup> Ablate-and-pace therapy should be considered when rhythm control therapy is unsuccessful.<sup>47</sup> After AV-node ablation, patients become pacemaker dependent, which may lead to pacing-induced cardiomyopathy.<sup>48</sup> Technical improvements increased the interest in conduction system pacing (CSP).<sup>49</sup> Conduction system pacing might be the most appropriate pacing mode for avoiding the development of pacing-induced cardiomyopathy<sup>50</sup> and is already used in patients treated with ablate-and-pace rate control.<sup>51</sup> Outcome studies are planned or ongoing (CONDUCT-AF, LBBAP-AFHF, RAFT-P&A, and others) and reviewed elsewhere.<sup>52</sup>

## Practical considerations and summary

Most patients with AF should undergo at least one attempt of active rhythm management during the first year after AF is diagnosed. In patients with AF and concomitant heart failure with reduced ejection fraction, rhythm management should be introduced as a fifth pillar on top of the established 'fantastic 4' [an angiotensin receptor–neprilysin inhibitor, a beta-blocker, a mineralocorticoid receptor antagonist, and a sodium-glucose co-transporter (SGLT) 2 inhibitor] for comprehensive

**Table 1** New antiarrhythmic drugs and new formulations of existing antiarrhythmic drugs in development

Novel antiarrhythmic agents				
Agent (developer)	Main antiarrhythmic target	Indication	Formulation	Current clinical status
AP30663	Small conductance calcium-activated potassium (SK) channel blocker	Cardioversion of recent-onset AF	Intravenous	Phase 2 completed (NCT04571385)
AP31969	Small conductance calcium-activated potassium (SK) channel blocker	Sinus rhythm maintenance	Oral	Phase 1 ongoing
HSY244	Undisclosed	Cardioversion of recent-onset AF	Intravenous	Phase 2 terminated (business decision) (NCT04582409)
HBI-3000 (sulcardine)	Multi-channel blocker	Cardioversion of recent-onset AF (>2 and <72 h)	Intravenous	Phase 2 ongoing (NCT04680026)
Budiodarone	Multi-channel blocker	Sinus rhythm maintenance	Oral	Phase 2 completed (PASCAL)
Botulinum toxin A	Cholinergic neurotransmission blocker	Prevention of postoperative AF	Injection around ganglionated plexuses	Phase 2 (NCT01842529; NOVA)
Reformulation of already approved AADs				
Antiarrhythmic drug	Main antiarrhythmic target	Indication	Reformulation	Current clinical status
Flecainide	Sodium channel blocker	Cardioversion of recent-onset symptomatic AF	Inhalation solution	Phase 2 terminated (NCT05039359; RESTORE-1) Phase 3 currently on hold (NCT03539302; INSTANT)
Repurposing of already approved medications				
Agent (developer)	Main antiarrhythmic target	Indication	Formulation	Current clinical status
Bucindolol	Beta 1 adrenergic blockade and receptor reduction	Sinus rhythm maintenance	Oral	Phase 2 completed (NCT01970501; GENETIC-AF)
Doxapram	TASK 1 inhibitor	Cardioversion of recent-onset AF	Intravenous	Phase 2 ongoing (EudraCT 2018-002979-17; DOCTOS)
Ranolazine	Late sodium channel blocker with minor effect on HERG channel	Sinus rhythm maintenance following cardioversion Reduction in AF burden in paroxysmal AF: Ranolazine and dronedarone given alone and in combination	Oral	Phase 2 completed (NCT01534962; RAFFAELLO)
			Oral	Phase 2 completed (NCT01522651)

Published results of completed studies are explained in more details, including references, in the text.

heart failure management strategies.<sup>53</sup> In light of the emerging role of AF therapy in heart failure patients, electrophysiologists with knowledge in rhythm control, AF ablation, and ablate-and-pace therapies should be an integral part of heart failure teams.

### Knowledge gaps and opportunities

- (1) Quantification of arrhythmia burden, number, and duration of recurrent episodes is needed to better understand the emerging link between AF burden and cardiovascular events. The outcome-reducing effects of rhythm control therapy may be mediated by reducing AF burden and attaining sinus rhythm. This questions the relevance of the primary outcome of older rhythm control trials and time to the first AF recurrence.<sup>3,15,16</sup>
- (2) Antiarrhythmic drugs and AF ablation exert synergistic rhythm-controlling effects.<sup>54,55</sup> More research is needed evaluating the effectiveness of antiarrhythmic drugs in the context of AF ablation.
- (3) Most of the clinical trials evaluating rhythm control therapy so far were conducted in relatively young patients with AF. The outcome-reducing effect of early rhythm control therapy, in contrast, was most pronounced in patients with AF and a high comorbidity burden (CHA<sub>2</sub>DS<sub>2</sub>-VASc score 4 or more).<sup>23</sup> There is a clear unmet need to evaluate rhythm control, including AF ablation, in patients with AF and a high comorbidity burden.
- (4) More research is needed to define the best methodology to deliver rhythm control therapy for all, integrating innovations in antiarrhythmic drug therapy and AF ablation.
- (5) Future research in the field of rate control should focus on patient selection and timing of ablate-and-pace therapy. Studies that include multiple arms with AF ablation compared with AV-node ablation with CSP are necessary to guide clinical practice.
- (6) Quantification of AF burden in drug trials, especially in trials of heart failure and in trials of new antiarrhythmic drugs, is needed to determine their effect on the association of AF burden reduction and prevention of AF-related outcomes.

## Atrial fibrillation burden in patients with electrocardiogram-diagnosed atrial fibrillation and in patients with device-detected atrial fibrillation

Longer rhythm monitoring durations lead to a higher likelihood of detecting rare and short AF episodes, thereby increasing the number of patients with AF.<sup>56</sup> This has been conceptually described in earlier iterations of the AFNET/EHRA consensus conference.<sup>57</sup> Intermittent electrocardiogram (ECG) recordings or 24-h ambulatory ECG monitors detect fewer patients with AF than continuous rhythm monitoring, mainly diagnosing AF in patients with a high arrhythmia burden.<sup>56,58,59</sup> The growing availability of consumer electronics capable of detecting and quantifying arrhythmia episodes will make such information more widely available in the near future.<sup>60–62</sup>

### Device-detected atrial fibrillation and electrocardiogram-documented atrial fibrillation

This group, including investigators from NOAH-AFNET 6 and ARTESiA, recommends to use the term 'device-detected AF' in preference to 'atrial high-rate episodes' and 'sub-clinical AF'. This recommendation is based on the following observations: A careful, core-lab-based analysis of all episodes leading to inclusion into NOAH-AFNET 6 revealed that 97% of these episodes showed all signs of AF.<sup>63</sup> Despite small differences in sensitivity and specificity, the algorithms for


recognition of device-detected AF are mature and have been validated and refined over time.<sup>64</sup> The differences in outcomes, e.g. the lower rate of stroke, between device-detected AF and ECG-documented AF is unlikely to be related to differences in the signals recorded during an episode. The term device-detected AF has been used by others after the publication of NOAH-AFNET 6 and ARTESiA<sup>9,65</sup> and can simplify thinking and discussion around this phenomenon.

It remains unclear which patient and what AF burden merits oral anticoagulation to prevent AF-related complications such as death, stroke, thromboembolism, and other morbidities or mortality. At present, the distinction between ECG-documented AF and device-detected AF draws a boundary that has developed historically. Electrocardiogram-documented AF selects patients with a high AF burden. In the absence of documented ECG-diagnosed AF, randomized clinical trials performed so far have failed to demonstrate a benefit of therapy with oral anticoagulation, including patients with embolic stroke of undetermined source,<sup>66,67</sup> patients with heart failure,<sup>68,69</sup> or patients with atrial cardiomyopathy, but without AF.<sup>70</sup> Existing evidence that shows the effectiveness of oral anticoagulation in patients with paroxysmal and persistent AF is based on trials enrolling patients with ECG-diagnosed AF (often requiring at least two AF ECG documentations within 1 year as an inclusion criterion, which likely represents a high AF burden). The STROKESTOP study randomized (1:1) > 75-year-olds to be invited to screening for AF by a handheld ECG 2x/day for 2 weeks or to a control group.<sup>71</sup> Treatment with oral anticoagulants upon ECG documentation of AF reduced the primary combined endpoint of ischaemic or haemorrhagic stroke, systemic embolism, bleeding leading to hospitalization, and all-cause death {hazard ratio 0.96 [95% confidence interval (CI) 0.92–1.00]; *P* = 0.045}. Studies initiating anticoagulation based on AF detection by continuous rhythm monitoring by implantable cardiac monitors in the LOOP study<sup>72</sup> or based on device-detected AF found by 24/7 rhythm monitoring via implantable cardiac devices in NOAH-AFNET 6<sup>1</sup> and ARTESiA<sup>4</sup> found a low event rate without anticoagulation, including a rate of stroke of 1%/year.<sup>9</sup> A sub-analysis from NOAH-AFNET 6 suggests that the low rate of stroke without anticoagulation extends to patients with long episodes of only device-detected AF ≥ 24 h.<sup>8</sup> The absolute treatment effects were the prevention of three strokes and an increase of seven to 16 major bleeds per 1000 patient-years.<sup>9</sup> These effects are probably not sufficient to recommend anticoagulation in patients with device-detected AF. Refined classifications of AF patterns<sup>73</sup> and ideally AF burden should be incorporated in outcome trials investigating the efficacy of modern rhythm control strategies.

Continuous (e.g. by implantable loop recorders) or semi-continuous (e.g. by wearable digital devices) long-term rhythm monitoring can provide information on AF burden, number of AF episodes, and duration of longest AF episode.<sup>74</sup> The average burden of device-detected AF in the absence of ECG-documented AF is low in patients with multiple comorbidities (0.13% median AF burden in LOOP<sup>75</sup>). Recent data from the RACE V registry suggest that paroxysmal AF has a higher burden that can be further differentiated into subgroups.<sup>76,77</sup> While continuous rhythm monitoring is the preferred method to evaluate AF burden, serial longer-term monitor<sup>10,78</sup> or even long-term intermittent monitoring by recording one to three short-term handheld ECGs per day provides effective, albeit less precise alternative methods.<sup>79</sup> So far, these rhythm monitoring methods have mainly been used in research settings.<sup>80–82</sup>

### Practical considerations and summary

This group believes that ECG-diagnosed AF should be differentiated from device-detected AF in clinical care (Figure 3). The biological rationale is most likely a higher arrhythmia burden in patients with ECG-documented AF.<sup>43</sup> Electrocardiogram-documented AF remains a reason to initiate anticoagulation,<sup>10</sup> provide active rhythm management (see above), and treat cardiovascular comorbidities. Detection of device-detected AF by implanted devices should, in contrast, trigger



ECG monitoring to diagnose AF. Treatment of concomitant conditions that can lead to AF can be intensified upon detection of device-detected AF to prevent AF progression. The outcomes of NOAH-AFNET 6<sup>1</sup> and ARTESiA<sup>4</sup> with a small reduction of ischaemic stroke in the context of a low overall rate of stroke and with an expected increase in major but non-fatal bleedings provide solid information for a shared decision process on anticoagulation in selected patients with device-detected AF.

### Knowledge gaps and hurdles

- (1) The amount of AF that distinguishes low and high burden of AF, the interaction of arrhythmia burden with comorbidities, and the best methods to quantify AF burden require more research. To estimate this, research needs to include quantification of arrhythmia burden in patients with paroxysmal AF with an assessment of the extent of AF burden reduction achieved by active rhythm management and how this relates to prevention of AF-related outcomes.<sup>83</sup>
- (2) Reducing AF burden is an emerging therapeutic goal in patients with AF based on this consensus document. Similar thoughts can be found in the recently published ACC/AHA/HRS AF guidelines.<sup>20</sup> The best methods to reduce AF burden in patients with different AF patterns and clinical situations need to be determined.
- (3) Uncertainty also remains about the best management of patients with arrhythmias detected by wearables and handheld devices. These devices semi-continuously monitor rhythm, enable an estimation of arrhythmia burden, and are used by increasing numbers of individuals.<sup>10,74,84</sup>
- (4) This group believes that quantifiable markers for AF-related disease processes are needed to enable this research. Further research is needed to explore the interaction between the number and severity of stroke risk factors, arrhythmia burden, and individual risk.
- (5) Another important line of research should describe the range of arrhythmia progression and regression patterns found in patients and factors identifying patients who are unlikely to experience progression to ECG-documented AF.

- (6) Based on the NOAH-AFNET 6 sub-study in patients with device-detected AF episodes  $\geq 24$  h,<sup>8</sup> it remains unclear whether detection of device-detected AF episodes  $\geq 24$ -h duration is equivalent to progression to 'clinical' AF.
- (7) The clinical relevance and utility of AF patterns and AF progression and regression detected by long-term rhythm monitoring need to be better understood to guide personalized treatments for AF.
- (8) Finally, more precise methods are needed to identify patients with device-detected AF at risk of stroke.


### Improved stroke prevention

The current clinical assessment of stroke risk using the CHA<sub>2</sub>DS<sub>2</sub>-VASc score<sup>85</sup> is limited by several factors, including the following:

- (1) modest predictive ability of contemporary risk prediction scores with the potential for over-/under-treatment due to imprecise risk estimation<sup>86</sup> and variable stroke rates across different populations (leading to inaccurate assessment of risk/benefit)<sup>87,88</sup>;
- (2) the emergence of newer therapeutic interventions, such as early rhythm control therapy,<sup>14</sup> left atrial appendage removal or closure,<sup>89</sup> and others<sup>65</sup> that reduce stroke risk without having systemic antithrombotic effects; and
- (3) the emergence of 'lower risk' AF populations not considered by traditional risk prediction schema, illustrated by patients with device-detected AF who show a relatively low stroke risk despite older age and multiple comorbidities.

These recent developments reinforce earlier calls<sup>90</sup> for improved and dynamic risk stratification schemes to re-evaluate the decision to use anticoagulants. Atrial fibrillation burden, concentrations of circulating biomolecules, and cardiovascular imaging parameters (e.g. atrial cardiomyopathy) have shown potential to improve and refine stroke risk prediction. At the same time, direct evidence is accumulating that AF therapy not only reduces stroke but also reduces heart failure events and cardiovascular death.<sup>3,14</sup>





**Figure 4** Refined risk assessment resulting in improved stroke risk prediction compared with traditional risk schemas. A longitudinal re-assessment of stroke risk may trigger adjustment of therapy (intensified therapies or de-escalation of therapy). AF, atrial fibrillation; ECG, electrocardiogram.

### Clinical risk factors

Clinical stroke risk factors, summarized as the CHA<sub>2</sub>DS<sub>2</sub>-VASc score, are clinically used to start oral anticoagulation in patients with AF. Consideration of additional clinical features such as chronic kidney disease, tobacco use, ventricular hypertrophy,<sup>91</sup> hypertrophic cardiomyopathy, amyloid, and other inherited cardiac conditions may offer further discriminative ability.

### Genetic risk

Initiated by the pioneering work in the population of Iceland,<sup>92</sup> a large body of data science now provides robust risk scores for AF and stroke based on genetic information.<sup>93,94</sup> These scores allow us to quantify AF and stroke risk with a five-fold range between the lowest-risk and highest-risk sub-populations.<sup>93,94</sup> Genetic risk alleles have been associated with recurrent AF on rhythm control therapy,<sup>95,96</sup> and AF risk scores can be used to predict the effectiveness of early rhythm control therapy.<sup>97</sup> Stroke risk can be refined by using genetic risk scores for stroke<sup>98,99</sup> and especially genetic changes related to both stroke and AF.<sup>100</sup> Recent data suggest that the genetic risk for AF overlaps with the genetic risk for heart failure, especially when rare variants are considered.

### Atrial fibrillation burden

As discussed above, AF burden emerges as a promising modulator of stroke risk. Early rhythm management reduces cardiovascular events, including a numerical 30% reduction in ischaemic stroke, in anticoagulated patients.<sup>14</sup> This effect is of a comparable magnitude to surgical removal of the left atrial appendage during open heart surgery.<sup>89</sup>

### Biomolecules

Circulating biomolecules play an important role in the diagnosis and management of patients with cardiovascular disease.<sup>101</sup> Several biomolecules have shown an independent added value for risk stratification in patients with AF.<sup>86</sup> The biomarker-based ABC-AF stroke and bleeding risk scores [Age, Biomarkers (N-terminal pro-B-type natriuretic peptide, troponin, haemoglobin, and GDF-15), Clinical history of stroke/TIA or bleeding in


Atrial Fibrillation] improve prediction of stroke and bleeding.<sup>86</sup> Newer biomolecules that can be accurately quantified include fibroblast growth factor 23 and bone morphogenetic protein 10 (BMP10).<sup>102</sup> Elevated concentrations of these biomolecules are associated with prevalent<sup>102</sup> and recurrent AF<sup>103,104</sup> and with AF-related outcomes.<sup>105</sup>

### Imaging

Atrial cardiomyopathy summarizes the histologic and anatomical disease processes that may lead to the development of AF, contribute to its recurrence and progression, and potentially enhance the risk of AF-related cardiovascular events. Left atrial size, a simple integral of atrial cardiomyopathy, has been variably associated with stroke and systemic embolism. Anticoagulation did not prevent strokes in patients with atrial cardiomyopathy, but without AF (ARCADIA),<sup>70</sup> adding to the evidence that AF is a required interacting factor for atrial cardiomyopathy to create a stroke risk. Atrial fibrosis, which can be visualized using late gadolinium enhancement cardiac magnetic resonance imaging, has been associated with an increased risk for major adverse cardiovascular and cerebrovascular events in patients with AF, primarily driven by increased risk for the occurrence of stroke or transient ischaemic attack.<sup>106</sup> More recently, echocardiographic parameters of left atrial function, including left atrial strain and left atrial appendage flow velocity, have been proposed as refined methods to quantify atrial cardiomyopathy and as risk modulators in patients with AF.

### Longitudinal reassessment of risk and adjustment of therapy

Most patients with ECG-documented AF should be on oral anticoagulation to reduce their risk of stroke. Atrial fibrillation is a dynamic disease, progressing and regressing from self-terminating to sustained arrhythmia episodes.<sup>107</sup> Stroke risk increases with age or in the context of disease progression and new comorbidities. Stroke risk will decrease with early rhythm control,<sup>14</sup> especially when sinus rhythm is attained,<sup>26</sup> with better treatment of concomitant cardiovascular conditions, or with spontaneous regression of AF burden.



**Figure 5** A risk factor and comorbidity management clinic according to the ‘Adelaide’ model: the risk factor and comorbidity management clinic is separated from the atrial fibrillation clinic and has a single healthcare professional who (i) initiates risk factor modification, (ii) identifies risk factors according to HEAD 2 TOES, (iii) sets achievable goals, and (iv) monitors progress towards habitual change. AF, atrial fibrillation; BMI, body mass index.

**Table 2** Various groups of artificial intelligence

	<b>Supervised machine learning</b>	<b>Unsupervised machine learning</b>	<b>Supervised deep learning</b>	<b>Unsupervised deep learning</b>
	Decision trees, support vector machines, random forest, boosted trees, etc.	Clustering, anomaly detection, dimensionality reduction, principal component analysis	Convolutional neural networks, recurrent neural networks, transformers, etc.	Autoencoders or generative adversarial networks
<b>Feature</b>	Input: quantified pre-defined individual features incl. annotation in training set <ul style="list-style-type: none"> <li>• Transparent</li> <li>• Interpretable</li> <li>• Able to handle high dimensional and non-linear data sets</li> <li>• Feature-based training with annotated data required</li> <li>• Unknown features ignored</li> </ul>	Input: quantified individual features <ul style="list-style-type: none"> <li>• Transparent</li> <li>• Interpretable</li> <li>• Classification based on pre-defined features</li> <li>• No training</li> </ul>	Input: pre-defined individual features, and/or raw signals or images, incl. annotation in training set <ul style="list-style-type: none"> <li>• Large training/validation data set required</li> <li>• Interpretation requires post-processing</li> <li>• Transparency limited (black box)</li> </ul>	Input: raw signals or images <ul style="list-style-type: none"> <li>• Independent of choice of preselected features</li> <li>• Able to classify based on unknown features</li> <li>• Large training/validation data set required</li> <li>• Interpretation requires post-processing (e.g. saliency mapping)</li> <li>• Transparency limited (black box)</li> </ul>
<b>Output</b>	Classification based on pre-defined features in pre-defined classes	Automatized classification in unknown number of not pre-defined classes <ul style="list-style-type: none"> <li>• Provides information on underlying structure or patterns</li> </ul>	Classification based on pre-defined and/or extracted features in pre-defined classes <ul style="list-style-type: none"> <li>• Classification problems based on large number of variables</li> </ul>	Classification based on raw signals or image analysis in which unidentified features might carry diagnostic or predictive information. Generation of synthetic signal or images.

There is a residual risk of ischaemic stroke despite anticoagulant therapy (1–2%/year in the pivotal randomized controlled trials), calling for augmented therapy.<sup>65,108,109</sup> Patients experiencing a stroke on anticoagulation can potentially benefit from a call to A-C-T-I-O-N to improve outcome.<sup>110</sup> Sub-optimal treatment of comorbidities and treatment with anticoagulation and low, untested, and non-approved doses<sup>111</sup> may contribute to stroke and cardioembolism.<sup>109</sup> The effects of LAAOS III<sup>89</sup> and EAST-AFNET 4<sup>14</sup> highlight the potential of treating atrial causes of stroke in patients with AF experiencing a stroke on anticoagulation. Whether novel FXIa inhibitors,<sup>112,113</sup> a distinct new class of drugs under investigation for thrombosis prevention, improve outcomes in patients with AF will be evaluated in ongoing registration trials. Phase 3 trial of asundexian in patients with AF has recently been stopped early due to lack of efficacy.<sup>114</sup> Trials with other compounds are ongoing.

### Practical considerations and summary

Guideline-recommended risk prediction schemes are useful to guide the initial decision for oral anticoagulation. Genetic risk scores, imaging, and circulating biomolecules may be able to refine this initial assessment. Longitudinal assessment of dynamic risk modulators integrating AF burden, atrial myopathy, and circulating biomolecules of cardiovascular and inflammatory origin can improve risk prediction. Such dynamic risk assessment can result in intensified and combination therapies and in de-escalation of therapy (Figure 4).

### Knowledge gaps and research opportunities


- (1) Research is needed to evaluate novel quantitative risk predictors, including AF-burden, circulating biomolecules, imaging, and genetic markers and their effect on improving prediction of stroke risk, and

prediction of the risk of other AF-related complications such as heart failure and cardiovascular death.

- (2) Randomized clinical trials to prospectively evaluate biomarker-based risk scores for therapy selection and proteomic screening to better understand the pathophysiology of AF complications are ongoing.
- (3) Evaluation of organ-specific atrial (e.g. BMP10) and cerebral health (e.g. neurofilament light chain polypeptide) biomolecules is ongoing with promising initial results. Biomolecules may also provide quantitative proxies for cardiac and atrial fibrosis.
- (4) In addition to new randomized trials, individual participant data meta-analysis will generate adequate power to assess the risks and benefits of anticoagulation in patients at different risks.<sup>115</sup> This is currently addressed in a collaborative effort of the AF SCREEN and the AFFECT-EU consortia as well as in COMBINE-AF.<sup>116</sup>
- (5) Stroke risk also appears low after AF ablation.<sup>117–124</sup> Randomized studies such as OCEAN<sup>125</sup> (NCT02168829) will determine whether the stroke risk after successful AF ablation is sufficiently reduced to withhold oral anticoagulation. REACT-AF (NCT05836987) will assess smartwatch-guided anticoagulation.

## Risk factor and comorbidity management for secondary prevention of atrial fibrillation

A healthy lifestyle and effective treatment of concomitant cardiovascular conditions, often embedded in integrated care pathways, improve maintenance of sinus rhythm and quality of life,<sup>126–130</sup> in addition to the outcome-reducing effect in larger populations.<sup>131,132</sup> Managing individual risk factors in isolation, such as excessive alcohol consumption, can improve AF outcomes.<sup>133</sup> Similarly, behavioural weight loss<sup>126,127,130</sup> and bariatric surgery can prevent AF outcomes in severely



obese individuals.<sup>134–138</sup> Weight loss–inducing glucagon-like peptide (GLP)-1 receptor antagonists, e.g. orforglipron, semaglutide, and tirzepatide, can reduce cardiovascular events and may reduce AF in obese populations.<sup>139–142</sup> While regional patterns of care will vary, integrated risk factor and comorbidity management clinics and specialists can improve the prevention and treatment of concomitant conditions in patients with AF.<sup>127,130</sup> The concept of risk factor and comorbidity management for secondary prevention of AF can be exemplified by the ‘Adelaide’ model: In Adelaide, the risk factor and comorbidity management clinic are separated from the AF clinic,<sup>143</sup> while both services share a unified messaging emphasizing the importance of treatment of concomitant cardiovascular conditions. This risk factor and comorbidity management clinic have a single healthcare professional who uses academic detailing and structured education visits to build rapport, educate, engage and empower individuals to make informed decisions, set achievable goals, and monitor progress towards habitual behavioural change. Comorbidity treatment and risk factor modification can follow the ‘HEAD 2 TOES’ acronym (Figure 5),<sup>144</sup> enhanced by treatment of coronary artery disease and valvular disease.<sup>145</sup> While a single healthcare professional (not a ‘village’ of co-located healthcare professionals) primarily manages most aspects of risk factor and comorbidity management, appropriate referrals may be used as required and available. Remote consulting and digital health approaches incorporated in such referral structures may not replace but will support these inter-disciplinary referral structures for the management of comorbidities in patients treated in established AF clinics.<sup>146,147</sup> Importantly, genetic testing may be valuable for identifying underlying conditions in young patients without apparent identifiable factors, which may have not yet manifested as cardiomyopathies (see prior

sections).<sup>148</sup> Pharmacological treatment of type-2 diabetes with SGLT2 inhibitors (Odds ratio 0.83, 95% CI 0.68–1.01)<sup>149</sup> or GLP-1 receptor agonists (Relative risk 0.86, 95% CI 0.76–0.97),<sup>150</sup> hypertension, vascular disease, and importantly of heart failure will have AF-reducing effects in addition to the outcome-reducing effects of these medications,<sup>151,152</sup> including treatment with SGLT2 inhibitors<sup>153–157</sup> and with finerenone.<sup>158</sup>

## Practical considerations and summary

The presence of AF, probably including device-detected AF, should trigger treatment of concomitant cardiovascular conditions. To improve universal access and adoption of these treatments,<sup>159</sup> the participants of the 9th AFNET/EHRA consensus conference propose to implement integrative risk management clinics to improve this treatment domain in patients with AF.

## Knowledge gaps and hurdles

- (1) Lifestyle improvement interventions and pharmacological treatments need to be tested at scale.<sup>160</sup> A large randomized controlled study spanning different geographies and healthcare models focusing on hard endpoints such as mortality, stroke, and hospitalization and equally cost-effectiveness measures such as quality-adjusted life-year is needed.<sup>161</sup>
- (2) Local institutional infrastructures and funding models have been identified as barriers to implementing risk factor and comorbidity management clinics in a recent survey.<sup>159</sup> The H2020 consortium EHRA-PATHS (EU grant agreement ID: 945260) aims to develop new systematic care pathways for the management of AF-related comorbidities across Europe.<sup>162</sup>

- (3) Little is known about the direct antiarrhythmic properties of novel heart failure medications: Their antiarrhythmic mechanisms are not well understood and their effect on AF and AF-related outcomes requires robust quantification. Prospective trials are needed and ongoing.
- (4) A comparative study of GLP-1 receptor therapy and surgical and behavioural weight loss is needed to determine their relative antiarrhythmic effectiveness, safety, and cost-effectiveness.
- (5) Furthermore, whether phenotyping of patients with AF may allow appropriate characterization of AF and identification of possible underlying causes that have specific treatment (e.g. hypertrophic cardiomyopathy—myosin inhibitors) requires further research.

## Artificial intelligence in the detection and management of atrial fibrillation and stroke

Since the 6th AFNET/EHRA consensus conference, artificial intelligence (AI) and modern data science techniques have been a topic during each AFNET/EHRA consensus conference.<sup>10,12,163</sup> There has been progress in the research implementation of AI and the provision of explainable AI to improve stroke prevention, rhythm management, and comorbidity management.<sup>164,165</sup> Artificial intelligence consists of supervised and unsupervised methodologies. In supervised learning, the output or target is defined (e.g. recognition of a sinus rhythm or AF on the ECG). The learning process uses labelled data sets to solve classification and regression or prediction problems. In unsupervised learning, there is no prediction of any output or need for labelled data.<sup>165</sup> Data are sub-divided into classes that were not pre-specified and that are agnostic to the purpose of the investigation. An important domain of AI is machine learning, of which deep learning is an important sub-domain.<sup>164</sup> Deep learning is typically a feedforward artificial neural network, where each node is an activation function that can produce an output signal if the sum of the inputs exceeds a certain threshold level.<sup>165</sup> These techniques are often used for classification purposes based on unspecified features extracted from imaging data or ECGs. In *Table 2* and *Figure 6*, the various groups of AI techniques, their dominant features and outputs, and potential applications are summarized.

A growing clinical and consumer use of AI is the automated detection of AF episodes in ECG and sensor recordings (e.g. photoplethysmography and gyroscopes)<sup>61,74,166–168</sup>; AI models can also enhance AF prediction based on ECG during sinus rhythm,<sup>169,170</sup> chest X-ray,<sup>171</sup> or facial photoplethysmography signals using a digital camera.<sup>172</sup> Deep-learning models have been used for the prediction of recurrent AF on rhythm control therapy.<sup>173,174</sup> In addition, ECG analysis using AI has been applied to guide the identification of patients with low ejection fraction<sup>175</sup> and predict ischaemic stroke risk in AF patients.<sup>176</sup>

### Explainable artificial intelligence

One of the rate-limiting factors for further implementation of AI in AF research and clinical practice is the black box nature of AI methods. The reliance on non-transparent AI algorithms raises concerns regarding understanding the systems' output and also about the responsibility and accountability for these outputs. To overcome this limitation, much effort has recently been invested in 'explainable AI' technology. Visualization techniques like attention maps, saliency maps, or heatmaps can highlight input variables and their effect direction within a structured data set, underscoring their importance and their influence on model decisions. Highlighting significant segments in ECGs or visualizing decision-making in structured data sets can provide insights that can be interpreted based on mechanistic understanding.<sup>170,177–180</sup> Additionally, the availability of generic frameworks enables the visualization of decisions from various

deep neural networks, making them applicable to multiple data sources, including structured data sets.<sup>181</sup>

### Knowledge gaps and research opportunities

- (1) Artificial intelligence approaches have become essential tools for researchers to integrate data of a distinct nature such as genetics, cardiac tissue structure including atrial fat, biomolecules, information on comorbidities, and transcriptome data. This strategy requires sharing of multi-modal data coming from different centres, processing of data through the complex steps of regulatory, interoperability, annotation, pseudonymization, and then centralizing data in a data hub to generate and use algorithms.<sup>182</sup> This is the goal of the European H2020 consortium MAESTRIA (EU grant agreement ID: 965286), which was created in 2021 bringing together 18 academic and private partners including AFNET.
- (2) For primary prevention strategy to prevent the development of AF and reduction of AF burden, AI can help to integrate information from multi-dimensional clinical parameters to create biomarkers that can inform on AF risk and risk of AF progression.<sup>183</sup>
- (3) Whether the use of AI-generated risk markers can guide AF therapy<sup>184,185</sup> requires clinical evaluation, e.g. in the EU-funded MAESTRIA consortium in its prospective AFNET-10 cohort of patients with different types of AF.
- (4) In addition, federated learning techniques offer opportunities for model development independent from the logistic challenges of data transfer, which warrants further investigations.

## Summary

The conference attendees identified several changes in the management of patients with AF supported by good evidence:

- (1) Active rhythm control therapy combined with rate control should be part of the default initial management of most patients with AF.
- (2) Biomolecules, genetics, and imaging parameters may help to refine the risk of stroke and other AF-related complications and to identify patient groups with likely therapy failure.
- (3) The stroke rate in patients with device-detected AF is low. Oral anticoagulation can reduce this low rate of stroke and induce major bleeding in patients with device-detected AF. More research is needed to identify patients with device-detected AF at high risk of stroke.
- (4) The presence of AF should trigger treatment of concomitant cardiovascular conditions, as already implemented for patients with coronary artery disease. The evidence for such measures drawn from research in patients with AF data sets supports wide-spread implementation.
- (5) Detection of AF and other chronic cardiovascular diseases is one of the first applications of unsupervised and supervised data science techniques. Iterative cooperation between clinicians and data scientists is needed to leverage the potential of data science and artificial explainable intelligence applications for patients with AF.

### Acknowledgements

We wish to thank all participants of the 9th AFNET/EHRA consensus conference and the staff of AFNET, EHRA, and ESC for the excellent organization of the conference.

### Funding

The 9th AFNET/EHRA consensus conference was co-financed by AFNET, EHRA, and the MAESTRIA consortium (EU grant agreement ID: 965286). Industry participants paid an attendance fee for the conference and provided an industry perspective during the discussions at the meeting but had no involvement in the writing process.

**Conflict of interest:** The 9th AFNET/EHRA consensus conference was partially supported by the European Union MAESTRIA project (grant agreement 965286) to AFNET. The following participants and authors are employees of companies active in cardiovascular health as indicated in

their affiliations: M.D.M., E.D., C.E., G.H., L.H.H., T.H., R.H.v.L., M.W., and H.W. P.K. was partially supported by the European Union AFFECT-AF (grant agreement 847770) and MAESTRIA (grant agreement 965286), German Center for Cardiovascular Research supported by the German Ministry of Education and Research (DZHK, grant numbers DZHK FKZ 81X2800182, 81Z0710116, and 81Z0710110), German Research Foundation (Ki 509167694), and Leducq Foundation. He receives research support for basic, translational, and clinical research projects from several drug and device companies active in AF and has received honoraria from several such companies in the past, but not in the last 3 years. He is listed as an inventor on two issued patents held by the University of Hamburg (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). J.G.A. was partially supported by the Canadian Arrhythmia Network and the Michael Smith Foundation for Health Research, Baylis Medical. He receives consulting fees/honoraria from Bayer, BMS/Pfizer Alliance, Servier, and Medtronic Inc. E.A. receives consulting fees/honoraria from Biosense Webster and Bayer. G.B. receives consulting fees/honoraria from Bayer, BMS, Boston Scientific, Daiichi Sankyo, Sanofi, and Janssen. A.J.C. receives consulting fees/honoraria from Bayer, Pfizer/BMS, Daiichi Sankyo, Menarini, Sanofi, Boston Scientific, Biosense Webster, Abbott, Acesion Pharma, Huya Bio, and Milestone. V.C. receives consulting fees/honoraria from Bayer, Boehringer Ingelheim, and Ever Pharma (paid to the institution of employment). W.D. receives consulting fees/honoraria from Reata and research grants from MicroPort, Boston Scientific, and Abbott. S.Z.D. receives consulting fees from BMS/Pfizer, Cortrium, and Acesion Pharma and speaker fees from MS/Pfizer and Bayer. He is listed as a medical advisor for Vital Beats. Dobromir D. receives consulting fees/honoraria from Elsevier, Springer Healthcare Ltd, and Daiichi Sankyo and research grants as follows: four NIH grants (partially) from Baylor College of Medicine, Houston; one NIH grant from UC Davis, one NIH grant from the University of Minnesota, and one EU-Project H2020. David D. receives consulting fees/honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientific, BMS/Pfizer, CVRx, Medtronic, MicroPort, and Zoll and research grants from Roche, CVRx, and Zoll. L.E. has received lecture fees from various companies in AF in the past but none related to the present work. L.F. receives consulting fees/honoraria from Roche (paid to the institution of employment). She is currently employed at the UKE and previously at the University of Birmingham. She was partially supported by the European Union AFFECT-EU (grant agreement 847770), MAESTRIA (grant agreement 965286), CATCH ME (grant agreement 633196), and the British Heart Foundation (AA/18/2/3218). D.F.-R. receives research grants from Abbott. He is listed as an inventor on two issued patents: EP3636147A1 (method for the identification of cardiac fibrillation drivers and/or the footprint of rotational activations) and PCT/EP2022/071364 (system and method of assessment of electromechanical remodelling). A.G. receives consulting fees/honoraria from Daiichi Sankyo, Bayer, BMS/Pfizer, Medtronic, Abbott, and Boston Scientific and was partially supported by the European Union MAESTRIA (grant agreement 965286). K.G.H. receives consulting fees/honoraria from Abbott, Alexion, Amarin, Astra Zeneca, Bayer Healthcare, Biotronik, Boehringer Ingelheim, Boston Scientific, BMS/Pfizer, Daiichi Sankyo, Edwards Lifesciences, Medtronic, Novartis, Portola, Premier Research, Sanofi, SUN Pharma, and W. L. Gore and Associates. J.S.H. receives speaking fees from BMS/Pfizer, Bayer, Servier, and Boston Scientific and consulting fees from Bayer and Boston Scientific. He receives research grants from BMS/Pfizer, Servier, Novartis, Boston Scientific, and Medtronic. H.H. receives lecture and consulting fees from Bayer, Biotronik, BMS/Pfizer, Daiichi Sankyo, Milestone Pharmaceuticals, Centrix India, C.T.I. Germany, ESC, Medscape, and Springer Healthcare Ltd. He receives research grants (paid to the institution of employment, University of Antwerp and/or University of Hasselt) from Abbott, Bayer, Biosense Webster, Boston Scientific, Daiichi Sankyo, Fibrichex/Qompium, Medtronic, and BMS/Pfizer. Z.H. receives consulting fees/honoraria from Boehringer Ingelheim, BMS/Pfizer, and Roche Diagnostics. He was partially supported by The Swedish Society for Medical Research (S17-0133), Hjärt-Lungfonden (The Swedish Heart-Lung Foundation, 20200722), and the institution he is currently employed at (Uppsala University Hospital). L.H.-M. receives research grants from the Spanish Ministry of Science and Innovation (PID2020-116927RB-C21) and Fondo Europeo de Desarrollo Regional (FEDER). D.K. receives consulting fees/honoraria from Bayer,

Amomed, and Protherics Medicines Development. He receives research grants from the National Institute for Health Research (NIHR CDF-2015-08-074 RAE-AF; NIHR130280 DaRe2THINK; NIHR13274 D2T-NeuroVascular; and NIHR203326 Biomedical Research Centre), the British Heart Foundation (PG/17/55/33087, AA/18/2/3218, and FS/CDRF/21/21032), the EU/EFPIA Innovative Medicines Initiative (BigData@Heart 116074), EU Horizon and UKRI (HYPERMARKER 101095480) UK National Health Service—Data for R&D-Subnational Secure Data Environment programme, UK Department for Business, Energy Industrial Strategy Regulators Pioneer Fund, the Cook & Wolstenholme Charitable Trust, and the European Society of Cardiology supported by educational grants from Boehringer Ingelheim, BMS/Pfizer, Alliance, Bayer, Daiichi Sankyo, Boston Scientific, the NIHR/University of Oxford Biomedical Research Centre, and the British Hear Foundation, the University of Birmingham Accelerator Award (STEEER-AF). J.L.M. receives consulting fees/honoraria from Biotronik, Medtronic, MicroPort, and Milestone Pharmaceuticals. A.M. receives consulting fees/honoraria from Medtronic, Biosense Webster, and Boston Scientific and lecture fees from Medtronic, Boston Scientific, Biosense Webster, BMS, and Bayer. L.M. receives consulting fees/honoraria from Abbott, Medtronic, Boston Scientific, and Johnson & Johnson. G.A.N. receives lecture fees from AliveCor, consultant fees from Biosense Webster, and research grants from Abbott and Biosense Webster. H.P. receives consulting fees/honoraria from Abbott, Boston Scientific, Biosense Webster, Medtronic, Daiichi Sankyo, Bayer, and Pfizer. P.S. receives consulting fees/honoraria from Medtronic, Boston Scientific, Abbott, CathRx, and PaceMate (paid to the institution of employment). He is currently employed at the University of Adelaide, which receives research grants from Medtronic, Boston Scientific, and Becton-Dickenson. R.B.S. receives consulting fees/honoraria from BMS/Pfizer. She was partially supported by the European Union Horizon 2020 research and innovation programme (grant agreement 648131 and 847770), German Center for Cardiovascular Research supported by the German Ministry of Education and Research (DZHK, grant numbers 81Z1710103 and 81Z0710114), German Ministry of Research and Education (BMBF 01ZX1408A), ERACoSysMed3 (031L0239), Wolfgang Seefried project funding German Heart Foundation. U.S. receives consulting fees/honoraria from University Svizzera Italiana, Stanford, and Johnson & Johnson and research grants from the European Union, Dutch Heart Foundation, Roche, and EP Solution. He is a shareholder of YourRhythmics B.V. T.T. receives consulting fees/honoraria from Boston Scientific and Medtronic. I.C.v.G. receives consulting fees/honoraria from Bayer (paid to the institution of employment). She is currently employed at the University of Groningen. K.V. receives consulting fees/honoraria from Abbott, Philips, Medtronic, Biosense Webster, and Boston Scientific and research grants from Medtronic and Biosense Webster. R.W. receives consulting fees/honoraria from Boehringer Ingelheim, BMS/Pfizer, Daiichi Sankyo, Boston Scientific, Biotronik, Abiomed, and Zoll and a research grant from Boston Scientific, BMS/Pfizer, and Abiomed. S.W. receives consulting fees/honoraria from Boehringer Ingelheim, Boston Scientific, Abbott, and Bayer Vital and a research grant from Boston Scientific. All remaining authors (G.B., J.C.N., T.D.P., N.D., M.F., E.G., S.H., S.K., D.L., K.M.-R., M.O., A.S.P., U.R., M.R., D.S., C.S., G.S., D.S., S.T., R.H.v.L., and S.Z.) have declared no conflicts of interest.

## Data availability

All data used for this report are publicly available, and their sources are cited. For further information, please contact [info@kompetenznetzvorhofflimmern.de](mailto:info@kompetenznetzvorhofflimmern.de).

## References

- Kirchhof P, Toennis T, Goette A, Camm AJ, Diener HC, Becher N et al. Anticoagulation with edoxaban in patients with atrial high-rate episodes. *N Engl J Med* 2023;**389**:1167–79.
- Reddy VY, Gerstenfeld EP, Natale A, Whang W, Cuoco FA, Patel C et al. Pulsed field or conventional thermal ablation for paroxysmal atrial fibrillation. *N Engl J Med* 2023;**389**:1660–71.
- Sohns C, Fox H, Marrouche NF, Crijns H, Costard-Jaeckle A, Bergau L et al. Catheter ablation in end-stage heart failure with atrial fibrillation. *N Engl J Med* 2023;**389**:1380–9.

4. Healey JS, Lopes RD, Granger CB, Alings M, Rivard L, McIntyre WF et al. Apixaban for stroke prevention in subclinical atrial fibrillation. *N Engl J Med* 2024;**390**:107–17.
5. Connolly S, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S et al. Apixaban in patients with atrial fibrillation. *N Engl J Med* 2011;**364**:806–17.
6. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med* 2011;**365**:883–91.
7. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M et al. Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2011;**365**:981–92.
8. Becher N, Toennis T, Bertaglia E, Blomstrom-Lundqvist C, Brandes A, Cabanelas N et al. Anticoagulation with edoxaban in patients with long atrial high-rate episodes  $\geq$ 24 hours. *Eur Heart J* 2024;**45**:837–49.
9. McIntyre WF, Benz AP, Becher N, Healey JS, Granger CB, Rivard L et al. Direct oral anticoagulants for stroke prevention in patients with device-detected atrial fibrillation: a study-level meta-analysis of the NOAH-AFNET 6 and ARTESiA trials. *Circulation* 2023. doi: 10.1161/CIRCULATIONAHA.123.067512
10. Schnabel RB, Marinelli EA, Arbelo E, Boriani G, Boveda S, Buckley CM et al. Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET/EHRA consensus conference. *Europace* 2023;**25**:6–27.
11. Fabritz L, Crijns H, Guasch E, Goette A, Hausler KG, Kotecha D et al. Dynamic risk assessment to improve quality of care in patients with atrial fibrillation: the 7th AFNET/EHRA consensus conference. *Europace* 2021;**23**:329–44.
12. Kotecha D, Breithardt G, Camm AJ, Lip GYH, Schotten U, Ahlsson A et al. Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA consensus conference. *Europace* 2018;**20**:395–407.
13. Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC et al. Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. *Europace* 2007;**9**:1006–23.
14. Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A et al. Early rhythm-control therapy in patients with atrial fibrillation. *N Engl J Med* 2020;**383**:1305–16.
15. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L et al. Catheter ablation for atrial fibrillation with heart failure. *N Engl J Med* 2018;**378**:417–27.
16. Willems S, Borof K, Brandes A, Breithardt G, Camm AJ, Crijns H et al. Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial. *Eur Heart J* 2022;**43**:1219–30.
17. Kim D, Yang PS, You SC, Sung JH, Jang E, Yu HT et al. Treatment timing and the effects of rhythm control strategy in patients with atrial fibrillation: nationwide cohort study. *BMJ* 2021;**373**:n991.
18. Kany S, Cardoso VR, Bravo L, Williams JA, Schnabel R, Fabritz L et al. Eligibility for early rhythm control in patients with atrial fibrillation in the UK Biobank. *Heart* 2022;**108**:1873–80.
19. Dickow J, Kirchhof P, Van Houten HK, Sangaralingham LR, Dinshaw LHW, Friedman PA et al. Generalizability of the EAST-AFNET 4 trial: assessing outcomes of early rhythm-control therapy in patients with atrial fibrillation. *J Am Heart Assoc* 2022;**11**:e024214.
20. Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM et al. ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. *Circulation* 2024;**149**:e1–156.
21. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. *N Engl J Med* 2009;**360**:668–78.
22. Connolly SJ, Crijns HJ, Torp-Pedersen C, van Eickels M, Gaudin C, Page RL et al. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. *Circulation* 2009;**120**:1174–80.
23. Rillig A, Borof K, Breithardt G, Camm AJ, Crijns H, Goette A et al. Early rhythm control in patients with atrial fibrillation and high comorbidity burden. *Circulation* 2022;**146**:836–47.
24. Packer DL, Piccini JP, Monahan KH, Al-Khalidi HR, Silverstein AP, Noseworthy PA et al. Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial. *Circulation* 2021;**143**:1377–90.
25. Metzner A, Suling A, Brandes A, Breithardt G, Camm AJ, Crijns H et al. Anticoagulation, therapy of concomitant conditions, and early rhythm control therapy: a detailed analysis of treatment patterns in the EAST—AFNET 4 trial. *Europace* 2022;**24**:552–64.
26. Eckardt L, Sehner S, Suling A, Borof K, Breithardt G, Crijns H et al. Attaining sinus rhythm mediates improved outcome with early rhythm control therapy of atrial fibrillation: the EAST-AFNET 4 trial. *Eur Heart J* 2022;**43**:4127–44.
27. Goette A, Borof K, Breithardt G, Camm AJ, Crijns H, Kuck KH et al. Presenting pattern of atrial fibrillation and outcomes of early rhythm control therapy. *J Am Coll Cardiol* 2022;**80**:283–95.
28. Blomstrom-Lundqvist C, Gizurarson S, Schwieler J, Jensen SM, Bergfeldt L, Kenneback G et al. Effect of catheter ablation vs antiarrhythmic medication on quality of life in patients with atrial fibrillation: the CAPTAF randomized clinical trial. *JAMA* 2019;**321**:1059–68.
29. Al-Kaisey AM, Parameswaran R, Bryant C, Anderson RD, Hawson J, Chieng D et al. Atrial fibrillation catheter ablation vs medical therapy and psychological distress: a randomized clinical trial. *JAMA* 2023;**330**:925–33.
30. Andrade JG, Deyell MW, Macle L, Wells GA, Bennett M, Essebag V et al. Progression of atrial fibrillation after cryoablation or drug therapy. *N Engl J Med* 2023;**388**:105–16.
31. Verma A, Jang CY, Betts TR, Chen J, Deisenhofer I, Mantovan R et al. Approaches to catheter ablation for persistent atrial fibrillation. *N Engl J Med* 2015;**372**:1812–22.
32. Kistler PM, Chieng D, Sugumar H, Ling LH, Segan L, Azzopardi S et al. Effect of catheter ablation using pulmonary vein isolation with vs without posterior left atrial wall isolation on atrial arrhythmia recurrence in patients with persistent atrial fibrillation: the CAPLA randomized clinical trial. *JAMA* 2023;**329**:127–35.
33. Marrouche NF, Wazni O, McGann C, Greene T, Dean JM, Dagher L et al. Effect of MRI-guided fibrosis ablation vs conventional catheter ablation on atrial arrhythmia recurrence in patients with persistent atrial fibrillation: the DECAAF II randomized clinical trial. *JAMA* 2022;**327**:2296–305.
34. Huo Y, Gaspar T, Schönbauer R, Wójcik M, Fiedler L, Roithinger FX et al. Low-voltage myocardium-guided ablation trial of persistent atrial fibrillation. *NEJM Evidence* 2022;**1**:EVID0a2200141.
35. Doll N, Weimar T, Kosior DA, Bulava A, Mokracek A, Monnig G et al. Efficacy and safety of hybrid epicardial and endocardial ablation versus endocardial ablation in patients with persistent and longstanding persistent atrial fibrillation: a randomised, controlled trial. *EClinicalMedicine* 2023;**61**:102052.
36. van der Heijden CAJ, Weberndörfer V, Vroomen M, Luermans JG, Chaldoupi SM, Bidar E et al. Hybrid ablation versus repeated catheter ablation in persistent atrial fibrillation: a randomized controlled trial. *JACC Clin Electrophysiol* 2023;**9**:1013–23.
37. Boersma L, Andrade JG, Betts T, Duytschaever M, Purerfellner H, Santoro F et al. Progress in atrial fibrillation ablation during 25 years of Europace journal. *Europace* 2023;**25**:eua244.
38. Clarnette JA, Brooks AG, Mahajan R, Elliott AD, Twomey DJ, Pathak RK et al. Outcomes of persistent and long-standing persistent atrial fibrillation ablation: a systematic review and meta-analysis. *Europace* 2018;**20**:366–76.
39. Tilz RR, Schmidt V, Purerfellner H, Maury P, Chun K, Martinek M et al. A worldwide survey on incidence, management, and prognosis of oesophageal fistula formation following atrial fibrillation catheter ablation: the POTTER-AF study. *Eur Heart J* 2023;**44**:2458–69.
40. Ekanem E, Reddy VY, Schmidt B, Reichlin T, Neven K, Metzner A et al. Multi-national survey on the methods, efficacy, and safety on the post-approval clinical use of pulsed field ablation (MANIFEST-PF). *Europace* 2022;**24**:1256–66.
41. Saljic A, Heijman J, Dobrev D. Recent advances in antiarrhythmic drug therapy. *Drugs* 2023;**83**:1147–60.
42. Heijman J, Zhou X, Morotti S, Molina CE, Abu-Taha IH, Tekook M et al. Enhanced Ca(2+)-dependent SK-channel gating and membrane trafficking in human atrial fibrillation. *Circ Res* 2023;**132**:e116–33.
43. Holst AG, Tomcsanyi J, Vestbjerg B, Grunnet M, Sorensen US, Diness JG et al. Inhibition of the K(Ca)2 potassium channel in atrial fibrillation: a randomized Phase 2 trial. *Nat Med* 2024;**30**:106–11.
44. Van Gelder IC, Groenvelde HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM et al. Lenient versus strict rate control in patients with atrial fibrillation. *N Engl J Med* 2010;**362**:1363–73.
45. Kotecha D, Bunting KV, Gill SK, Mehta S, Stanbury M, Jones JC et al. Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: the RATE-AF randomized clinical trial. *JAMA* 2020;**324**:2497–508.
46. Brignole M, Pentimalli F, Palmisano P, Landolina M, Quartieri F, Occhetta E et al. AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial. *Eur Heart J* 2021;**42**:4731–9.
47. Rijks JHJ, Lankveld T, Manusama R, Broers B, Stipdonk A, Chaldoupi SM et al. Left bundle branch area pacing and atrioventricular node ablation in a single-procedure approach for elderly patients with symptomatic atrial fibrillation. *J Clin Med* 2023;**12**:4028.
48. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM et al. 2021 ESC guidelines on cardiac pacing and cardiac resynchronization therapy. *Europace* 2022;**24**:71–164.
49. Jastrzębski M, Kielbasa G, Cano O, Curila K, Heckman L, De Pooter J et al. Left bundle branch area pacing outcomes: the multicentre European MELOS study. *Eur Heart J* 2022;**43**:4161–73.
50. Palmisano P, Ziacchi M, Dell’Era G, Donato P, Ammendola E, Aspromonte V et al. Ablate and pace: comparison of outcomes between conduction system pacing and biventricular pacing. *Pacing Clin Electrophysiol* 2023;**46**:1258–68.
51. Kircanski B, Boveda S, Prinzen F, Sorgente A, Anic A, Conte G et al. Conduction system pacing in everyday clinical practice: EHRA physician survey. *Europace* 2023;**25**:682–7.

52. Tung R, Burri H. Role of conduction system pacing in ablate and pace strategies for atrial fibrillation. *Eur Heart J Suppl* 2023;**25**:G56–62.
53. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumach A, Bohm M et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* 2021;**42**:3599–726.
54. Darkner S, Chen X, Hansen J, Pehrson S, Johannessen A, Nielsen JB et al. Recurrence of arrhythmia following short-term oral AMIOdaron after CATHeter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). *Eur Heart J* 2014;**35**:3356–64.
55. Duytschaever M, Demolder A, Philips T, Sarkozy A, El Haddad M, Taghji P et al. Pulmonary vein isolation with vs. without continued antiarrhythmic Drug treatment in subjects with Recurrent Atrial Fibrillation (POWDER AF): results from a multicentre randomized trial. *Eur Heart J* 2018;**39**:1429–37.
56. Aguilar M, Macle L, Deyell MW, Yao R, Hawkins NM, Khairy P et al. Influence of monitoring strategy on assessment of ablation success and postablation atrial fibrillation burden assessment: implications for practice and clinical trial design. *Circulation* 2022;**145**:21–30.
57. Kirchhof P, Bax JJ, Blomstrom-Lundquist C, Calkins H, Camm AJ, Cappato R et al. Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'. *Eur Heart J* 2009;**30**:2969–2977c.
58. Charitos EI, Ziegler PD, Stierle U, Robinson DR, Graf B, Sievers HH et al. Atrial fibrillation burden estimates derived from intermittent rhythm monitoring are unreliable estimates of the true atrial fibrillation burden. *Pacing Clin Electrophysiol* 2014;**37**:1210–8.
59. Kirchhof P, Bax JJ, Blomstrom-Lundquist C, Calkins H, Camm AJ, Cappato R et al. Early and comprehensive management of atrial fibrillation: proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'. *Europace* 2009;**11**:860–85.
60. Fabritz L, Connolly DL, Czarnecki E, Dudek D, Guasch E, Haase D et al. Smartphone and wearable detected atrial arrhythmias in older adults: results of a fully digital European case finding study. *Eur Heart J Digit Health* 2022;**3**:610–25.
61. Perez MV, Mahaffey KW, Hedlin H, Rumsfeld JS, Garcia A, Ferris T et al. Large-scale assessment of a smartwatch to identify atrial fibrillation. *N Engl J Med* 2019;**381**:1909–17.
62. Lubitz SA, Atlas SJ, Ashburner JM, Lipsanopoulos ATT, Borowsky LH, Guan W et al. Screening for atrial fibrillation in older adults at primary care visits: VITAL-AF randomized controlled trial. *Circulation* 2022;**145**:946–54.
63. Kirchhof P, Schotten U, Zapf A. Anticoagulation with Edoxaban in patients with atrial high-rate episodes. Reply. *N Engl J Med* 2023;**389**:2302–3.
64. Mahajan R, Perera T, Elliott AD, Twomey DJ, Kumar S, Munwar DA et al. Subclinical device-detected atrial fibrillation and stroke risk: a systematic review and meta-analysis. *Eur Heart J* 2018;**39**:1407–15.
65. Seiffge DJ, Cancelloni V, Räber L, Paciaroni M, Metzner A, Kirchhof P et al. Secondary stroke prevention in people with atrial fibrillation: treatments and trials. *Lancet Neurol* 2024;**23**:404–417.
66. Diener HC, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchiyama S et al. Dabigatran for prevention of stroke after embolic stroke of undetermined source. *N Engl J Med* 2019;**380**:1906–17.
67. Hart RG, Sharma M, Mundt H, Kasner SE, Bangdiwala SI, Berkowitz SD et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. *N Engl J Med* 2018;**378**:2191–201.
68. Zannad F, Anker SD, Byra WM, Cleland JGF, Fu M, Gheorghiane M et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. *N Engl J Med* 2018;**379**:1332–42.
69. Vassiliki' Coutsoumbas G, Di Pasquale G. Ischaemic stroke in the absence of documented atrial fibrillation: is there who could benefit from anticoagulant therapy? *Eur Heart J Suppl* 2022;**24**:189–95.
70. Kamel H, Longstreth WT Jr, Tirschwell DL, Kronmal RA, Marshall RS, Broderick JP. Apixaban to prevent recurrence after cryptogenic stroke in patients with atrial cardiopathy: the ARCADIA randomized clinical trial. *JAMA* 2024;**331**:573–581.
71. Svennberg E, Friberg L, Frykman V, Al-Khalili F, Engdahl J, Rosenqvist M. Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group, unmasked, randomised controlled trial. *Lancet* 2021;**398**:1498–506.
72. Svendsen JH, Diederichsen SZ, Hojberg S, Krieger DW, Graff C, Kronborg C et al. Implantable loop recorder detection of atrial fibrillation to prevent stroke (the LOOP study): a randomised controlled trial. *Lancet* 2021;**398**:1507–16.
73. Charitos EI, Purerfellner H, Glotzer TV, Ziegler PD. Clinical classifications of atrial fibrillation poorly reflect its temporal persistence: insights from 1,195 patients continuously monitored with implantable devices. *J Am Coll Cardiol* 2014;**63**:2840–8.
74. Hermans ANL, Gawalko M, Dohmen L, van der Velden RMJ, Betz K, Duncker D et al. Mobile health solutions for atrial fibrillation detection and management: a systematic review. *Clin Res Cardiol* 2022;**111**:479–91.
75. Diederichsen SZ, Haugan KJ, Brandes A, Lanng MB, Graff C, Krieger D et al. Natural history of subclinical atrial fibrillation detected by implanted loop recorders. *J Am Coll Cardiol* 2019;**74**:2771–81.
76. De With RR, Erküner Ö, Rienstra M, Nguyen BO, Körver FWJ, Linz D et al. Temporal patterns and short-term progression of paroxysmal atrial fibrillation: data from RACE V. *Europace* 2020;**22**:1162–72.
77. van de Lande ME, Rama RS, Koldenhof T, Arita VA, Nguyen BO, van Deutekom C et al. Time of onset of atrial fibrillation and atrial fibrillation progression data from the RACE V study. *Europace* 2023;**25**:eua058.
78. Svennberg E, Caiani EG, Bruining N, Desteghe L, Han JK, Narayan SM et al. The digital journey: 25 years of digital development in electrophysiology from an *Europace* perspective. *Europace* 2023;**25**:eua0176.
79. Hermans ANL, Gawalko M, Pluymaekers N, Dinh T, Weijs B, van Mourik MJW et al. Long-term intermittent versus short continuous heart rhythm monitoring for the detection of atrial fibrillation recurrences after catheter ablation. *Int J Cardiol* 2021;**329**:105–12.
80. Kirchhof P, Andresen D, Bosch R, Borggrefe M, Meinertz T, Parade U et al. Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. *Lancet* 2012;**380**:238–46.
81. Goette A, Schon N, Kirchhof P, Breithardt G, Fetsch T, Hausler KG et al. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. *Circ Arrhythm Electrophysiol* 2012;**5**:43–51.
82. Kuck KH, Hoffmann BA, Ernst S, Wegscheider K, Treszl A, Metzner A et al. Impact of complete versus incomplete circumferential lines around the pulmonary veins during catheter ablation of paroxysmal atrial fibrillation: results from the gap-atrial fibrillation-German atrial fibrillation competence network 1 trial. *Circ Arrhythm Electrophysiol* 2016;**9**:e003337.
83. Schwennesen HT, Andrade JG, Wood KA, Piccini JP. Ablation to reduce atrial fibrillation burden and improve outcomes: JACC review topic of the week. *J Am Coll Cardiol* 2023;**82**:1039–50.
84. Svennberg E, Tjong F, Goette A, Akoum N, Di Biase L, Bordachar P et al. How to use digital devices to detect and manage arrhythmias: an EHRA practical guide. *Europace* 2022;**24**:979–1005.
85. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. *Eur Heart J* 2021;**42**:373–498.
86. Hijazi Z, Lindback J, Oldgren J, Benz AP, Alexander JH, Connolly SJ et al. Individual net clinical outcome with oral anticoagulation in atrial fibrillation using the ABC-AF risk scores. *Am Heart J* 2023;**261**:55–63.
87. Quinn GR, Severdija ON, Chang Y, Singer DE. Wide variation in reported rates of stroke across cohorts of patients with atrial fibrillation. *Circulation* 2017;**135**:208–19.
88. Lip GYH, Proietti M, Potpara T, Mansour M, Savelieva I, Tse HF et al. Atrial fibrillation and stroke prevention: 25 years of research at EP *Europace* journal. *Europace* 2023;**25**:eua0226.
89. Whitlock RP, Belley-Cote EP, Paparella D, Healey JS, Brady K, Sharma M et al. Left atrial appendage occlusion during cardiac surgery to prevent stroke. *N Engl J Med* 2021;**384**:2081–91.
90. Lubitz SA, Benjamin EJ, Ruskin JN, Fuster V, Ellinor PT. Challenges in the classification of atrial fibrillation. *Nat Rev Cardiol* 2010;**7**:451–60.
91. Kirchhof P, Breithardt G, Camm AJ, Crijns HJ, Kuck KH, Vardas P et al. Improving outcomes in patients with atrial fibrillation: rationale and design of the early treatment of atrial fibrillation for stroke prevention trial. *Am Heart J* 2013;**166**:442–8.
92. Gudbjartsson DF, Arnar DO, Helgadóttir A, Gretarsdóttir S, Holm H, Sigurdsson A et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. *Nature* 2007;**448**:353–7.
93. Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. *Nat Genet* 2018;**50**:1219–24.
94. O'Sullivan JW, Shcherbina A, Justesen JM, Turakhia M, Perez M, Wand H et al. Combining clinical and polygenic risk improves stroke prediction among individuals with atrial fibrillation. *Circ Genom Precis Med* 2021;**14**:e003168.
95. Shoemaker MB, Bollmann A, Lubitz SA, Ueberham L, Saini H, Montgomery J et al. Common genetic variants and response to atrial fibrillation ablation. *Circ Arrhythm Electrophysiol* 2015;**8**:296–302.
96. Shoemaker MB, Husser D, Roselli C, Al Jazairi M, Chrispin J, Kuhne M et al. Genetic susceptibility for atrial fibrillation in patients undergoing atrial fibrillation ablation. *Circ Arrhythm Electrophysiol* 2020;**13**:e007676.
97. Kany S, Al-Taie C, Roselli C, Pirruccello JP, Borof K, Reinbold C et al. Association of genetic risk and outcomes in patients with atrial fibrillation: interactions with early rhythm control in the EAST-AFNET4 trial. *Cardiovasc Res* 2023;**119**:1799–810.



98. Malik R, Chauhan G, Traylor M, Sargurupremraj M, Okada Y, Mishra A et al. Multi-ancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. *Nat Genet* 2018;**50**:524–37.
99. Mishra A, Malik R, Hachiya T, Jurgenson T, Namba S, Posner DC et al. Stroke genetics informs drug discovery and risk prediction across ancestries. *Nature* 2022;**611**:115–23.
100. Rosselli C, Chaffin MD, Weng LC, Aeschbacher S, Ahlberg G, Albert CM et al. Multi-ethnic genome-wide association study for atrial fibrillation. *Nat Genet* 2018;**50**:1225–33.
101. Hijazi Z, Oldgren J, Siegbahn A, Wallentin L. Application of biomarkers for risk stratification in patients with atrial fibrillation. *Clin Chem* 2017;**63**:152–64.
102. Chua W, Purmah Y, Cardoso VR, Gkoutos GV, Tull SP, Neculau G et al. Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation. *Eur Heart J* 2019;**40**:1268–76.
103. Reyat JS, Chua W, Cardoso VR, Witten A, Kastner PM, Kabir SN et al. Reduced left atrial cardiomyocyte PITX2 and elevated circulating BMP10 predict atrial fibrillation after ablation. *JCI Insight* 2020;**5**:e139179.
104. Chua W, Khashaba A, Canagarajah H, Blankenberg S, Cosedis Nielsen J, di Biase L et al. Disturbed atrial metabolism, shear stress, and cardiac load after AF ablation: AXAFA biomolecules study. *Europace* 2024;**26**:euae028.
105. Hijazi Z, Benz AP, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW et al. Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation. *Eur Heart J* 2023;**44**:208–18.
106. King JB, Azadani PN, Suksaranjit P, Bress AP, Witt DM, Han FT et al. Left atrial fibrosis and risk of cerebrovascular and cardiovascular events in patients with atrial fibrillation. *J Am Coll Cardiol* 2017;**70**:1311–21.
107. Heijman J, Linz D, Schotten U. Dynamics of atrial fibrillation mechanisms and comorbidities. *Annu Rev Physiol* 2021;**83**:83–106.
108. Meinel TR, Branca M, De Marchis GM, Nedeltchev K, Kahles T, Bonati L et al. Prior anticoagulation in patients with ischemic stroke and atrial fibrillation. *Ann Neurol* 2021;**89**:42–53.
109. Tutuncu S, Olma M, Kunze C, Dietzel J, Schurig J, Fiessler C et al. Off-label-dosing of non-vitamin K-dependent oral antagonists in AF patients before and after stroke: results of the prospective multicenter Berlin Atrial Fibrillation Registry. *J Neurol* 2022;**269**:470–80.
110. Karl Georg H. Ischaemic stroke in atrial fibrillation patients while on oral anticoagulation—a call for A-C-T-I-O-N. *Eur Heart J* 2023;**44**:1815–7.
111. Paciaroni M, Agnelli G, Caso V, Silvestrelli G, Seiffge DJ, Engelter S et al. Causes and risk factors of cerebral ischemic events in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants for stroke prevention. *Stroke* 2019;**50**:2168–74.
112. Galli M, Laborante R, Ortega-Paz L, Franchi F, Rollini F, D'Amario D et al. Factor XI inhibitors in early clinical trials: a meta-analysis. *Thromb Haemost* 2023;**123**:576–84.
113. Büller HR, Bethune C, Bhanot S, Gailani D, Monia BP, Raskob GE et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. *N Engl J Med* 2015;**372**:232–40.
114. Bayer. OCEANIC-AF Study Stopped Early Due to Lack of Efficacy. <https://www.bayer.com/media/en-us/oceanic-af-study-stopped-early-due-to-lack-of-efficacy/> (12 December 2023, date last accessed).
115. AF SCREEN and AFFECT-EU Collaborators. Protocol for a systematic review and individual participant data meta-analysis of randomized trials of screening for atrial fibrillation to prevent stroke. *Thromb Haemost* 2023;**123**:366–76.
116. Carnicelli AP, Hong H, Giugliano RP, Connolly SJ, Eikelboom J, Patel MR et al. Individual patient data from the pivotal randomized controlled trials of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (COMBINE AF): design and rationale: from the COMBINE AF (a collaboration between multiple institutions to better investigate non-vitamin K antagonist oral anticoagulant use in atrial fibrillation) investigators. *Am Heart J* 2021;**233**:48–58.
117. Oral H, Chugh A, Ozaydin M, Good E, Fortino J, Sankaran S et al. Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation. *Circulation* 2006;**114**:759–65.
118. Themistoclakis S, Corrado A, Marchlinski FE, Jais P, Zado E, Rossillo A et al. The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation. *J Am Coll Cardiol* 2010;**55**:735–43.
119. Hunter RJ, McCready J, Diab I, Page SP, Finlay M, Richmond L et al. Maintenance of sinus rhythm with an ablation strategy in patients with atrial fibrillation is associated with a lower risk of stroke and death. *Heart* 2012;**98**:48–53.
120. Bunch TJ, May HT, Bair TL, Weiss JP, Crandall BG, Osborn JS et al. Atrial fibrillation ablation patients have long-term stroke rates similar to patients without atrial fibrillation regardless of CHADS2 score. *Heart Rhythm* 2013;**10**:1272–7.
121. Saliba W, Schliamser JE, Lavi I, Barnett-Griness O, Gronich N, Rennert G. Catheter ablation of atrial fibrillation is associated with reduced risk of stroke and mortality: a propensity score-matched analysis. *Heart Rhythm* 2017;**14**:635–42.
122. Srivatsa UN, Danielsen B, Amsterdam EA, Pezeshkian N, Yang Y, Nordsieck E et al. CAABL-AF (California Study of Ablation for Atrial Fibrillation): mortality and stroke, 2005 to 2013. *Circ Arrhythm Electrophysiol* 2018;**11**:e005739.
123. Joza J, Samuel M, Jackevicius CA, Behlouli H, Jia J, Koh M et al. Long-term risk of stroke and bleeding post-atrial fibrillation ablation. *J Cardiovasc Electrophysiol* 2018;**29**:1355–62.
124. Packer DL, Mark DB, Robb RA, Monahan KH, Bahnsen TD, Poole JE et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. *JAMA* 2019;**321**:1261–74.
125. Verma A, Ha ACT, Kirchhof P, Hindricks G, Healey JS, Hill MD et al. The optimal anti-coagulation for enhanced-risk patients post-catheter ablation for atrial fibrillation (OCEAN) trial. *Am Heart J* 2018;**197**:124–32.
126. Abed HS, Wittter GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. *JAMA* 2013;**310**:2050–60.
127. Middeldorp ME, Pathak RK, Meredith M, Mehta AB, Elliott AD, Mahajan R et al. PREVENTion and regRESSive effect of weight-loss and risk factor modification on atrial fibrillation: the REVERSE-AF study. *Europace* 2018;**20**:1929–35.
128. Pathak RK, Elliott A, Middeldorp ME, Meredith M, Mehta AB, Mahajan R et al. Impact of CARDIOrespiratory FITness on arrhythmia recurrence in obese individuals with atrial fibrillation: the CARDIO-FIT study. *J Am Coll Cardiol* 2015;**66**:985–96.
129. Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. *J Am Coll Cardiol* 2014;**64**:2222–31.
130. Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX et al. Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY). *J Am Coll Cardiol* 2015;**65**:2159–69.
131. Chung MK, Eckhardt LL, Chen LY, Ahmed HM, Gopinathannair R, Joglar JA et al. Lifestyle and risk factor modification for reduction of atrial fibrillation: a scientific statement from the American Heart Association. *Circulation* 2020;**141**:e750–72.
132. Global Cardiovascular Risk C, Magnussen C, Ojeda FM, Leong DP, Alegre-Diaz J, Amouyel P et al. Global effect of modifiable risk factors on cardiovascular disease and mortality. *N Engl J Med* 2023;**389**:1273–85.
133. Voskoboinik A, Kalman JM, De Silva A, Nicholls T, Costello B, Nanayakkara S et al. Alcohol abstinence in drinkers with atrial fibrillation. *N Engl J Med* 2020;**382**:20–8.
134. Donnellan E, Aagaard P, Kanj M, Jaber W, Elshazly M, Hoosien M et al. Association between pre-ablation glycaemic control and outcomes among patients with diabetes undergoing atrial fibrillation ablation. *JACC Clin Electrophysiol* 2019;**5**:897–903.
135. Donnellan E, Wazni O, Kanj M, Hussein A, Baranowski B, Lindsay B et al. Outcomes of atrial fibrillation ablation in morbidly obese patients following bariatric surgery compared with a nonobese cohort. *Circ Arrhythm Electrophysiol* 2019;**12**:e007598.
136. Donnellan E, Wazni OM, Elshazly M, Kanj M, Hussein AA, Baranowski B et al. Impact of bariatric surgery on atrial fibrillation type. *Circ Arrhythm Electrophysiol* 2020;**13**:e007626.
137. Donnellan E, Wazni OM, Kanj M, Baranowski B, Cremer P, Harb S et al. Association between pre-ablation bariatric surgery and atrial fibrillation recurrence in morbidly obese patients undergoing atrial fibrillation ablation. *Europace* 2019;**21**:1476–83.
138. Donnellan E, Wazni OM, Kanj M, Elshazly M, Hussein AA, Patel DR et al. Impact of risk-factor modification on arrhythmia recurrence among morbidly obese patients undergoing atrial fibrillation ablation. *J Cardiovasc Electrophysiol* 2020;**31**:1979–86.
139. Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. *N Engl J Med* 2023;**389**:877–88.
140. Dandona P, Chaudhuri A, Ghanim H. Semaglutide in early type 1 diabetes. *N Engl J Med* 2023;**389**:958–9.
141. Frias JP, Davies MJ, Rosenstock J, Perez Manghi FC, Fernandez Lando L, Bergman BK et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. *N Engl J Med* 2021;**385**:503–15.
142. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. *N Engl J Med* 2023;**389**:2221–32.
143. Middeldorp ME, Ariyaratnam J, Lau D, Sanders P. Lifestyle modifications for treatment of atrial fibrillation. *Heart* 2020;**106**:325–32.
144. Elliott AD, Middeldorp ME, Van Gelder IC, Albert CM, Sanders P. Epidemiology and modifiable risk factors for atrial fibrillation. *Nat Rev Cardiol* 2023;**20**:404–17.
145. Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP et al. Incidence of and risk factors for atrial fibrillation in older adults. *Circulation* 1997;**96**:2455–61.
146. Verhaert DVM, Betz K, Gawalko M, Hermans ANL, Pliymaekers N, van der Velden RMJ et al. A VIRTUAL sleep apnoea management pathway for the work-up of atrial fibrillation patients in a digital remote infrastructure: VIRTUAL-SAFARI. *Europace* 2022;**24**:565–75.
147. van der Velden RMJ, Hereijgers MJM, Arman N, van Middendorp N, Franssen FME, Gawalko M et al. Implementation of a screening and management pathway for chronic obstructive pulmonary disease in patients with atrial fibrillation. *Europace* 2023;**25**:euaad193.
148. Yoneda ZT, Anderson KC, Ye F, Quintana JA, O'Neill MJ, Sims RA et al. Mortality among patients with early-onset atrial fibrillation and rare variants in cardiomyopathy and arrhythmia genes. *JAMA Cardiol* 2022;**7**:733–41.
149. Aziri B, Begic E, Jankovic S, Mladenovic Z, Stanetic B, Kovacevic-Preradovic T et al. Systematic review of sodium-glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure-related events. *ESC Heart Fail* 2023;**10**:1499–530.

150. Scheen AJ. Antidiabetic agents and risk of atrial fibrillation/flutter: a comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists. *Diabetes Metab* 2022;**48**:101390.
151. Coats AJS, Heymans S, Farmakis D, Anker SD, Backs J, Bauersachs J, et al. Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology. *Eur Heart J* 2022;**43**:863–867.
152. Mohammad Z, Ahmad J, Sultan A, Penagaluri A, Morin D, Dominic P. Effect of sacubitril-valsartan on the incidence of atrial fibrillation: a meta-analysis. *J Cardiovasc Electrophysiol* 2023;**34**:1037–42.
153. Solomon SD, Vaduganathan M, Claggett BL, de Boer RA, DeMets D, Hernandez AF, et al. Baseline characteristics of patients with HF with mildly reduced and preserved ejection fraction: DELIVER trial. *JACC Heart Fail* 2022;**10**:184–97.
154. Butt JH, Kondo T, Jhund PS, Comin-Colet J, de Boer RA, Desai AS, et al. Atrial fibrillation and dapagliflozin efficacy in patients with preserved or mildly reduced ejection fraction. *J Am Coll Cardiol* 2022;**80**:1705–17.
155. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. *N Engl J Med* 2021;**385**:1451–61.
156. Filippatos G, Farmakis D, Butler J, Zannad F, Ferreira JP, Ofstad AP, et al. Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation. *Eur J Heart Fail* 2023;**25**:970–7.
157. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. *N Engl J Med* 2021;**384**:117–28.
158. Filippatos G, Bakris GL, Pitt B, Agarwal R, Rossing P, Rullope LM, et al. Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes. *J Am Coll Cardiol* 2021;**78**:142–52.
159. Lee G, Baker E, Collins R, Merino JL, Desteghe L, Heidbuchel H. The challenge of managing multimorbid atrial fibrillation: a pan-European European Heart Rhythm Association (EHRA) member survey of current management practices and clinical priorities. *Europace* 2022;**24**:2004–14.
160. Gessler N, Willems S, Steven D, Aberle J, Akbulak RO, Gosau N, et al. Supervised obesity reduction trial for AF ablation patients: results from the SORT-AF trial. *Europace* 2021;**23**:1548–58.
161. Pathak RK, Evans M, Middeldorp ME, Mahajan R, Mehta AB, Meredith M, et al. Cost-effectiveness and clinical effectiveness of the risk factor management clinic in atrial fibrillation: the CENT study. *JACC Clin Electrophysiol* 2017;**3**:436–47.
162. Heidbuchel H, Van Gelder IC, Desteghe L. ESC and EHRA lead a path towards integrated care for multimorbid atrial fibrillation patients: the Horizon 2020 EHRA-PATHS project. *Eur Heart J* 2022;**43**:1450–2.
163. Fabritz L, Crijns H, Guasch E, Goette A, Haeusler KG, Kotecha D, et al. Dynamic risk assessment to improve quality of care in patients with atrial fibrillation. The 7th AFNET/EHRA consensus conference. *Europace* 2021;**23**:329–44.
164. Isaksen JL, Baumert M, Hermans ANL, Maleckar M, Linz D. Artificial intelligence for the detection, prediction, and management of atrial fibrillation. *Herzschrittmacherther Elektrophysiol* 2022;**33**:34–41.
165. Benjamins JW, van Leeuwen K, Hofstra L, Rienstra M, Appelman Y, Nijhof W, et al. Enhancing cardiovascular artificial intelligence (AI) research in the Netherlands: CVON-AI consortium. *Neth Heart J* 2019;**27**:414–25.
166. Noseworthy PA, Attia ZI, Behnken EM, Giblon RE, Bews KA, Liu S, et al. Artificial intelligence-guided screening for atrial fibrillation using electrocardiogram during sinus rhythm: a prospective non-randomised interventional trial. *Lancet* 2022;**400**:1206–12.
167. Guo Y, Wang H, Zhang H, Liu T, Liang Z, Xia Y, et al. Mobile photoplethysmographic technology to detect atrial fibrillation. *J Am Coll Cardiol* 2019;**74**:2365–75.
168. Hermans ANL, Isaksen JL, Gawalko M, Pluymaekers N, van der Velden RMJ, Snippe H, et al. Accuracy of continuous photoplethysmography-based 1 min mean heart rate assessment during atrial fibrillation. *Europace* 2023;**25**:835–44.
169. Attia ZI, Noseworthy PA, Lopez-Jimenez F, Asirvatham SJ, Deshmukh AJ, Gersh BJ, et al. An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome prediction. *Lancet* 2019;**394**:861–7.
170. Khurshid S, Friedman S, Reeder C, Di Achille P, Diamant N, Singh P, et al. ECG-based deep learning and clinical risk factors to predict atrial fibrillation. *Circulation* 2022;**145**:122–33.
171. Matsumoto T, Ehara S, Walston SL, Mitsuyama Y, Miki Y, Ueda D. Artificial intelligence-based detection of atrial fibrillation from chest radiographs. *Eur Radiol* 2022;**32**:5890–7.
172. Yan BP, Lai WHS, Chan CKY, Au ACK, Freedman B, Poh YC, et al. High-throughput, contact-free detection of atrial fibrillation from video with deep learning. *JAMA Cardiol* 2020;**5**:105–7.
173. Nuñez-García JC, Sánchez-Puente A, Sampedro-Gómez J, Vicente-Palacios V, Jiménez-Navarro M, Oterino-Manzanas A, et al. Outcome analysis in elective electrical cardioversion of atrial fibrillation patients: development and validation of a machine learning prognostic model. *J Clin Med* 2022;**11**:2636.
174. Tang S, Razeghi O, Kapoor R, Alhusseini MI, Fazal M, Rogers AJ, et al. Machine learning-enabled multimodal fusion of intra-atrial and body surface signals in prediction of atrial fibrillation ablation outcomes. *Circ Arrhythm Electrophysiol* 2022;**15**:e010850.
175. Yao X, Rushlow DR, Inselman JW, McCoy RG, Thacher TD, Behnken EM, et al. Artificial intelligence-enabled electrocardiograms for identification of patients with low ejection fraction: a pragmatic, randomized clinical trial. *Nat Med* 2021;**27**:815–9.
176. Jung S, Song MK, Lee E, Bae S, Kim YY, Lee D, et al. Predicting ischemic stroke in patients with atrial fibrillation using machine learning. *Front Biosci (Landmark Ed)* 2022;**27**:80.
177. Wouters PC, van de Leur RR, Vessies MB, van Stipdonk AMW, Ghossein MA, Hassink RJ, et al. Electrocardiogram-based deep learning improves outcome prediction following cardiac resynchronization therapy. *Eur Heart J* 2023;**44**:680–92.
178. Cohen-Shelly M, Attia ZI, Friedman PA, Ito S, Essayagh BA, Ko WY, et al. Electrocardiogram screening for aortic valve stenosis using artificial intelligence. *Eur Heart J* 2021;**42**:2885–96.
179. Ayano YM, Schwenker F, Dufera BD, Debelee TG. Interpretable machine learning techniques in ECG-based heart disease classification: a systematic review. *Diagnostics (Basel)* 2022;**13**:111.
180. van de Leur RR, Bos MN, Taha K, Sammani A, Yeung MW, van Duijvenboden S, et al. Improving explainability of deep neural network-based electrocardiogram interpretation using variational auto-encoders. *Eur Heart J Digit Health* 2022;**3**:390–404.
181. Ribeiro MT, Singh S, Guestrin C. “Why should i trust you?” Explaining the predictions of any classifier. In Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, KDD 2016, San Francisco, CA, USA.
182. Steffens S, Schröder K, Krüger M, Maack C, Streckfuss-Bömeke K, Backs J, et al. The challenges of research data management in cardiovascular science: a DGK and DZHK position paper-executive summary. *Clin Res Cardiol* 2023. doi: 10.1007/s00392-023-02303-3
183. Linz D, Verheule S, Isaacs A, Schotten U. Considerations for the assessment of substrates, genetics and risk factors in patients with atrial fibrillation. *Arrhythm Electrophysiol Rev* 2021;**10**:132–9.
184. Lebert J, Ravi N, Fenton FH, Christoph J. Rotor localization and phase mapping of cardiac excitation waves using deep neural networks. *Front Physiol* 2021;**12**:782176.
185. Liao S, Ragot D, Nayyar S, Suszko A, Zhang Z, Wang B, et al. Deep learning classification of unipolar electrograms in human atrial fibrillation: application in focal source mapping. *Front Physiol* 2021;**12**:704122.